12p12.1 Microdeletion Syndrome

Mendelian MONDO:0017781 Pathograph 7 Show in embeddings browser Neurodevelopmental Disorder Chromosomal Deletion Syndrome

The 12p12.1 microdeletion syndrome is the deletion form of Lamb-Shaffer syndrome, a neurodevelopmental disorder caused by haploinsufficiency of SOX5. The clinical picture is global developmental delay with disproportionately prominent speech delay, mild to moderate intellectual disability, behavioural features including autistic traits, and subtle characteristic facial features. The name is regional but the disease is not. Deletions at 12p12.1 were how the entity was found, but three other classes produce the same phenotype: intragenic deletions, truncating and missense point variants, and balanced translocations whose breakpoint falls inside SOX5. A translocation carries no copy-number change at all, and the affected individuals reported with one are clinically indistinguishable. Across the 83 variants reported up to 2023 the split is roughly even, 47 per cent single nucleotide variants against 53 per cent copy number variants, so neither class is a minority curiosity. The deleted region is not the disease-defining feature; loss of one functional SOX5 allele is, and this entry is curated on that basis with the deletion treated as one route to it. The strongest evidence that the region is not doing the work is that the smallest reported deletion narrows the critical interval to a segment containing SOX5 and nothing else. The missense variants are what make the haploinsufficiency claim more than an inference from gene dose. They cluster in the SOX-specific high-mobility-group domain, and the ones that do cluster there abolish DNA binding and transactivation in vitro, while missense variants elsewhere in the protein do neither and are generally better tolerated clinically. That is a structure-function-phenotype correspondence at three levels for one gene, and it is the strongest evidence in this entry. What is absent is equally worth stating: across a cohort of 41 patients no clear genotype-phenotype correlation was found beyond the tolerance of out-of-domain missense variants. Deletion size does not predict severity, and this entry therefore makes no claim that it does.

Ask OpenScientist

Ask a research question about 12p12.1 Microdeletion Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Inheritance
3
Pathophys.
12
Phenotypes
4
Gaps
7
Pathograph
1
Genes
1
Medical Actions
1
Models
10
References
1
Deep Research
🏷

Classifications

Harrison's Part
GENETICS ENVIRONMENT DISEASE NEUROLOGIC
🔗

Mappings

MONDO
MONDO:0017781 12p12.1 microdeletion syndrome
skos:exactMatch MONDO
The dismech entry and the MONDO class denote the same entity. The entry treats the concept as SOX5 haploinsufficiency rather than as a copy-number lesion, and records in notes that the MONDO label is narrower than the disease it names.
👪

Inheritance

1
Autosomal dominant HP:0000006
Autosomal dominant, and in the great majority of reported cases de novo. Parental gonadal mosaicism has been documented, which is the counselling point: a couple with one affected child and an apparently de novo variant does not have a negligible recurrence risk.
Autosomal dominant inheritance
Show evidence (1 reference)
PMID:36861937 SUPPORT DIRECT Human Clinical
"This cohort provides further evidence of gonadal mosaicism in SOX5 variants; this should be considered when providing genetic counseling for couples with one affected child and an apparently de novo variant."
States both the observation and the counselling consequence the authors draw from it.
?

Discussions and Knowledge Gaps

4
Is there any disease-modifying therapy for Lamb-Shaffer syndrome, or is management entirely symptomatic?
KNOWLEDGE GAP no_disease_modifying_therapy
Attached to
treatments#
The treatments section holds one row, and that row is a single-patient adverse-reaction report rather than a therapy. That thinness is a fact about the field rather than about the curation: the literature states plainly that no treatment exists. The gap is recorded so a reader does not mistake an almost-empty section for an unfinished one, and so that a future disease-modifying candidate has somewhere to attach.
Show evidence (1 reference)
PMID:40163633 SUPPORT DIRECT Human Clinical
"There is currently no treatment for LSS; however, robust understanding of LSS's heterogenous phenotypic and genetic profile will lead to improved knowledge of the syndrome and diagnostic aptitude."
States the absence of treatment directly. Quoted with the authors' forward-looking second clause intact, because trimming at the semicolon would make the sentence read as more final than it is.
Should this concept be named and modelled as a chromosomal microdeletion syndrome at all, given that most reported lesions are not deletions?
KNOWLEDGE GAP entity_is_gene_not_region
Attached to
disease#12p12.1 Microdeletion Syndrome pathophysiology#Loss of One Functional SOX5 Allele
MONDO:0017781 names a cytogenetic region and sits under "chromosome 12p deletion". The disease it labels is SOX5 haploinsufficiency, and in the most recent series nine of sixteen lesions were single nucleotide variants rather than deletions, while two reported patients have balanced translocations with no copy-number change at all. A region-named class implies that contiguous-gene effects matter, and nothing in the literature cited here suggests they do: no second gene in the interval has been implicated, and deletion size does not track severity. This entry is therefore curated as SOX5 haploinsufficiency with the deletion as one mutational class, and the mismatch between that and the MONDO label is recorded rather than papered over. It is an upstream question for MONDO whether Lamb-Shaffer syndrome should be the primary class.
Show evidence (2 references)
PMID:29477873 SUPPORT DIRECT Human Clinical
"Thus, the present patient has SOX5 haploinsufficiency affecting 2 long forms of SOX5 and is the second reported case of Lamb-Shaffer syndrome caused by a de novo balanced reciprocal translocation."
A patient with the disease and no deletion. This is the single observation that most directly undercuts a region-based definition.
PMID:23220431 SUPPORT DIRECT Human Clinical
"The smallest deletion helps to narrow down the critical region to a genomic segment (chr12:23,924,800-24,041,698, build 37/hg19) encompassing only one gene, SOX5."
Settles the "no second gene in the interval" claim from the deletion side rather than by absence of evidence. Intersecting deletions of different sizes leaves a critical region containing SOX5 alone, which is what a contiguous-gene account would have to contradict.
Why is the clinical severity of SOX5 haploinsufficiency so variable when the molecular lesion is uniform, and does the microcephaly signal in point-variant patients survive a larger cohort?
KNOWLEDGE GAP no_genotype_phenotype_correlation
Attached to
pathophysiology#Loss of One Functional SOX5 Allele phenotypes#Microcephaly
A 41-patient study found no clear genotype-phenotype correlation beyond the tolerance of out-of-domain missense variants, and severity nonetheless varies widely. Two readings are open. If the lesion really is uniform haploinsufficiency, the variability must come from modifiers or from the genetic background, and nothing has been done to look. Alternatively the lesions are not equivalent, and the later observation that point-variant patients tend toward lower growth parameters and microcephaly than deletion patients hints at that - which would be counterintuitive, since a whole-gene deletion is the more complete loss. That observation is a tendency in sixteen patients and needs replication before it is treated as a correlation. Until then this entry makes no claim that lesion class predicts severity.
Show evidence (2 references)
PMID:31578471 SUPPORT DIRECT Human Clinical
"No clear genotype-phenotype correlations were found, except that missense variants outside the high-mobility-group domain were generally better tolerated."
The negative result this gap is built on, stated in the largest available cohort, with its one exception.
PMID:31578471 SUPPORT DIRECT Human Clinical
"Clinical manifestations and severity varied among patients."
States the variability that the absent correlation fails to explain.
Does halving SOXFive in a human brain mistime corticofugal subtype generation the way abolishing it does in a mouse?
HUMAN MODEL MISMATCH no_model_system
Attached to
pathophysiology#Disrupted Neurodevelopmental Transcriptional Program animal_models#Mouse
This is a mismatch rather than an absence, which is why it is typed HUMAN_MODEL_MISMATCH. Evidence exists and it is good: the Sox5 null mouse identifies the programme SOX5 controls and shows precisely how its loss disorders corticofugal subtype timing. What it cannot establish is the step this disease turns on. The mouse is a homozygous null and every reported patient is heterozygous, so the experiment answers "is SOX5 required" and the disease asks "what does half of it do". A dosage-sensitive transcription factor is exactly the case where those can come apart. Two further gaps sit alongside it and are genuinely absences. No patient-derived neural material has been transcriptionally characterised, so the human targets are unidentified. And mouse corticogenesis lacks the expanded outer subventricular zone that shapes human cortical layering, so even a heterozygous mouse would leave a species question open. Until that is addressed, the mechanism node stays PROVISIONAL and no therapeutic target follows from it.
Show evidence (1 reference)
PMID:31578471 SUPPORT INDIRECT Human Clinical
"The present study was aimed at increasing our understanding of LAMSHF, its clinical and genetic spectrum, and the pathophysiological mechanisms involved."
The largest study of the disorder states mechanism as an aim, and what it delivered on that aim was the in vitro DNA-binding result rather than anything in neural tissue. INDIRECT: this supports the gap by what the literature does not contain.
⚙

Pathophysiology

3
Loss of One Functional SOX5 Allele
Mechanism confidence: Established
A heterozygous lesion that removes or disables one SOX5 allele. Four mutational classes are described and they converge here: microdeletions at 12p12.1, intragenic deletions, truncating and missense point variants, and balanced translocations with a breakpoint inside the gene. This node, rather than any one of those lesions, is what the entry is curated on.
Genetic context SOX5 hgnc:11201 HUGO Gene Nomenclature Committee (hgnc) Relation: this genetic context concerns this gene This genetic context concerns SOX5 (hgnc:11201). hgnc:11201 is a gene from the HUGO Gene Nomenclature Committee. variant_origin: GERMLINE zygosity: HETEROZYGOUS functional_impact_category: LOSS_OF_FUNCTION
Usually de novo. Parental gonadal mosaicism has been documented in at least one family, which matters for counselling: an apparently de novo variant does not guarantee a negligible recurrence risk.
DNA-binding transcription factor activity GO:0003700 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased DNA-binding transcription factor activity (GO:0003700). GO:0003700 is a molecular function from the Gene Ontology. ↓ DECREASED
Downstream
Impaired SOX5 DNA Binding and Transactivation For the missense class the mechanism is directly demonstrated rather than inferred from dose: variants in the high-mobility-group domain abolish both DNA binding and transactivation.
Show evidence (6 references)
PMID:31578471 SUPPORT DIRECT Human Clinical
"Microdeletions and truncating variants occurred throughout SOX5."
Establishes that the causal lesions are distributed across the gene rather than confined to the deleted region the syndrome is named after.
PMID:29477873 SUPPORT DIRECT Human Clinical
"Thus, the present patient has SOX5 haploinsufficiency affecting 2 long forms of SOX5 and is the second reported case of Lamb-Shaffer syndrome caused by a de novo balanced reciprocal translocation."
A patient with no copy-number change at all and the same disease, which is the observation that makes SOX5 dosage rather than the deleted interval the operative variable.
PMID:23220431 SUPPORT DIRECT Human Clinical
"The smallest deletion helps to narrow down the critical region to a genomic segment (chr12:23,924,800-24,041,698, build 37/hg19) encompassing only one gene, SOX5."
The strongest single statement that this is a one-gene disease rather than a contiguous-gene one. It reaches that conclusion from the deletion side, independently of the translocation case, by intersecting deletions of different sizes.
+ 3 more references
Impaired SOX5 DNA Binding and Transactivation
Mechanism confidence: Established
SOX5 fails to bind its target DNA and to drive transcription. The functional lesion is localised to the SOX-specific high-mobility-group domain, which is where the disease-associated missense variants cluster.
DNA-binding transcription factor activity GO:0003700 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves DNA-binding transcription factor activity (GO:0003700), qualified as loss of function. GO:0003700 is a molecular function from the Gene Ontology. ⇓ LOSS OF FUNCTION
Downstream
Disrupted Neurodevelopmental Transcriptional Program SOX5 regulates cell fate and differentiation during neurogenesis; halving its effective activity perturbs that program.
Show evidence (1 reference)
PMID:31578471 SUPPORT DIRECT Human Clinical
"In contrast, most missense variants clustered in the pivotal SOX-specific high-mobility-group domain."
The clustering is what links the structural domain to disease causation in patients, independently of the in vitro assay.
Disrupted Neurodevelopmental Transcriptional Program
Mechanism confidence: Provisional
The downstream transcriptional consequence in the developing nervous system. Mouse genetics gives this node real content rather than leaving it a placeholder: losing SOX5 causes the three principal sequentially born corticofugal neuron subtypes to overlap in identity, because SOX5 normally prevents later-born subtypes from appearing early. So the program SOX5 controls is a temporal one, and the defect is mistiming of subtype generation rather than failure of neurogenesis as such. The node is PROVISIONAL rather than ESTABLISHED for a specific reason, not as a hedge. The mouse result comes from a homozygous null, and the human lesion is a heterozygous dosage reduction; whether halving SOX5 mistimes the same programme is not shown. Nor has the transcriptional programme been characterised in any patient-derived neural material. Those are two different gaps and the second is recorded separately.
central nervous system development GO:0007417 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased central nervous system development (GO:0007417). GO:0007417 is a biological process from the Gene Ontology. ↓ DECREASED
Animal models
Sox5 null mouse Mouse partially recapitulates Identifies the programme SOX5 controls - temporal ordering of corticofugal neuron subtype generation - and shows what its loss does to that ordering.
Downstream
Global Developmental Delay The clinical expression of the disrupted program.
Delayed Speech and Language Development Speech delay is disproportionately prominent relative to the general developmental delay, which is the feature clinicians use to recognise the syndrome.
Show evidence (2 references)
PMID:31578471 SUPPORT INDIRECT Human Clinical
"Lamb-Shaffer syndrome (LAMSHF) is a neurodevelopmental disorder described in just over two dozen patients with heterozygous genetic alterations involving SOX5, a gene encoding a transcription factor regulating cell fate and differentiation in neurogenesis and other discrete developmental processes."
States SOX5's normal role in neurogenesis in the human-genetics literature.
PMID:18215621 SUPPORT INDIRECT Model Organism
"We report that the transcription factor SOX5 controls the sequential generation of distinct corticofugal neuron subtypes by preventing premature emergence of normally later-born corticofugal neurons."
Identifies what the disrupted programme actually is: temporal control of corticofugal subtype generation. INDIRECT because the experiment is a mouse homozygous null and the human disease is a heterozygous dosage lesion, so the step to this node in humans is an inference across both species and zygosity.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for 12p12.1 Microdeletion Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

12
Eye 4
Ophthalmic Involvement FREQUENT Strabismus HP:0000486 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Strabismus (HP:0000486). HP:0000486 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:40180173 SUPPORT DIRECT Human Clinical
"Up to 57% of patients have ophthalmic findings, including strabismus, refractive error, and optic nerve abnormalities."
Gives both the frequency and the three component findings. Strabismus is bound as the HP term because it is the one named first and is the commonest; the other two are curated as their own phenotypes below.
PMID:40163633 SUPPORT DIRECT Human Clinical
"Ophthalmic manifestations of LSS such as strabismus and optic nerve abnormalities have been described in approximately 55% of patients with LSS."
An independent frequency estimate, 55 per cent against 57 per cent, which is close enough to treat the majority-prevalence claim as replicated rather than resting on one report.
Abnormality of Refraction HP:0000539 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormality of refraction (HP:0000539). HP:0000539 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:40180173 SUPPORT DIRECT Human Clinical
"Up to 57% of patients have ophthalmic findings, including strabismus, refractive error, and optic nerve abnormalities."
Names refractive error among the ophthalmic findings.
Optic Atrophy HP:0000648 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Optic atrophy (HP:0000648). HP:0000648 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:40180173 SUPPORT DIRECT Human Clinical
"We present 2 siblings who are the first documented cases of Lamb-Shaffer syndrome with the p.R571W: c.1711 C>T SOX5 mutation to demonstrate optic nerve atrophy."
Two siblings, and the report says so - this is the first documentation of optic atrophy in the syndrome, so it should be read as a new and thinly evidenced finding rather than an established feature.
Hypermetropia HP:0000540 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypermetropia (HP:0000540). HP:0000540 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37702321 SUPPORT DIRECT Human Clinical
"Strikingly, pain insensitivity and hypermetropia seems to be more frequent than previously reported, based on the frequency seen in the Spanish cohort."
Same sentence and same caveat as the pain-insensitivity row: a frequency impression from one cohort compared against prior reports, so no frequency band is asserted.
Head and Neck 2
Microcephaly HP:0000252 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Microcephaly (HP:0000252). HP:0000252 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36861937 SUPPORT DIRECT Human Clinical
"We expand in more detail on the behavioral phenotype and observe that there is a greater tendency toward lower growth parameters and microcephaly in patients with single nucleotide variants."
Reports both the finding and the genotype class it is associated with. The authors' own hedge, "a greater tendency toward", is preserved rather than converted into a correlation claim.
Facial Dysmorphism FREQUENT Abnormality of the face HP:0000271 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormality of the face (HP:0000271). HP:0000271 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:37702321 SUPPORT DIRECT Human Clinical
"Additionally, patients with the syndrome may present distinct facial dimorphism such as a wide mouth with full lips, small chin, broad nasal bridge, and deep-set eyes."
Enumerates the component features. Note the source's spelling, "dimorphism", is preserved as quoted rather than corrected.
PMID:37702321 SUPPORT DIRECT Human Clinical
"The most frequent features included developmental delay, intellectual disability, visual problems, poor speech development and facial dysmorphic features."
Places facial dysmorphism among the most frequent features, which is what the FREQUENT band rests on.
Nervous System 6
Global Developmental Delay HP:0001263 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Global developmental delay (HP:0001263). HP:0001263 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36861937 SUPPORT DIRECT Human Clinical
"As expected, the most common findings include global developmental delay with prominent speech delay, mild to moderate intellectual disability, behavioral abnormalities and sometimes subtle characteristic facial features."
Names global developmental delay as the most common finding.
Delayed Speech and Language Development HP:0000750 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Delayed speech and language development (HP:0000750). HP:0000750 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31578471 SUPPORT DIRECT Human Clinical
"This study extends the clinical and genetic spectrum associated with LAMSHF and consolidates evidence that SOX5 haploinsufficiency leads to variable degrees of intellectual disability, language delay, and other clinical features."
Names language delay as a consolidated feature of the syndrome.
Intellectual Disability HP:0001249 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intellectual disability (HP:0001249). HP:0001249 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36861937 SUPPORT DIRECT Human Clinical
"As expected, the most common findings include global developmental delay with prominent speech delay, mild to moderate intellectual disability, behavioral abnormalities and sometimes subtle characteristic facial features."
Gives both the finding and its usual severity band.
Autistic Behavior HP:0000729 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Autistic behavior (HP:0000729). HP:0000729 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:29477873 SUPPORT DIRECT Human Clinical
"This report confirmed that haploinsufficiency of the 2 long forms of SOX5 presents common clinical features, including mild intellectual disability and autistic features, which could be useful for the clinical diagnosis of Lamb-Shaffer syndrome."
Names autistic features among the common findings, in a patient ascertained through a translocation rather than a deletion.
Seizures OCCASIONAL HP:0001250 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Seizure (HP:0001250). HP:0001250 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39075495 SUPPORT DIRECT Human Clinical
"erature and this study showed intellectual disability, speech delay and facial dysmorphisms were common clinical manifestation, while the seizures and EEG abnormalities were rare (21/95, 22"
Gives the fraction and the authors' own reading of it. The quote begins mid-word because the cached abstract text is truncated at that point, and ends before the decimal for the same reason; the denominator is what matters here.
Pain Insensitivity HP:0007021 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pain insensitivity (HP:0007021). HP:0007021 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37702321 SUPPORT DIRECT Human Clinical
"Strikingly, pain insensitivity and hypermetropia seems to be more frequent than previously reported, based on the frequency seen in the Spanish cohort."
Reports the finding with the authors' own framing - a frequency impression from one cohort, explicitly compared against prior reports rather than measured against a denominator - so no frequency band is asserted here.
🧬

Genetic Associations

1
SOX5
Gene: SOX5 hgnc:11201 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is SOX5 (hgnc:11201). hgnc:11201 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (2 references)
PMID:31578471 SUPPORT DIRECT In Vitro
"The latter variants prevented SOX5 from binding DNA and promoting transactivation in vitro, whereas missense variants located outside the high-mobility-group domain did not."
Functional demonstration for the missense class, with the out-of-domain variants serving as an internal negative control.
PMID:29477873 SUPPORT DIRECT Human Clinical
"We determined the translocation breakpoints of the patient to be in intron 4 of SOX5 and the intergenic region in 20p12.3 via FISH and nucleotide sequence analyses."
Localises a disease-causing breakpoint inside SOX5, which is what makes a balanced rearrangement an SOX5 lesion rather than a positional coincidence.
💊

Medical Actions

1
Aripiprazole after Risperidone Intolerance
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Platform: Small molecule
Not a treatment recommendation, and it should not be read as one. A single reported child with Lamb-Shaffer syndrome developed paradoxical behavioural activation on very low-dose risperidone given for irritability and self-injury, and subsequently tolerated aripiprazole. It is curated because behavioural disturbance is a core part of this syndrome, psychotropic prescribing is therefore common, and this is the only disease-specific pharmacological observation in the literature - n=1, uncontrolled, and a paradoxical reaction to one agent in one child is not evidence about the class.
Show evidence (2 references)
PMID:41531626 SUPPORT DIRECT Human Clinical
"Data on psychotropic response profiles in Lamb-Shaffer syndrome are extremely limited."
Curated as its own evidence item because it is the qualifier that governs how the efficacy observation should be read, and there is no slot for a strength qualifier on the item it qualifies.
PMID:41531626 SUPPORT DIRECT Human Clinical
"We report a six-year-five-month-old boy with de novo Lamb-Shaffer syndrome, autism spectrum disorder (ASD) of mild-to-moderate severity, attention deficit hyperactivity disorder, and query intellectual disability who developed paradoxical behavioral activation after initiation of very low-dose..."
The observation itself, with its full denominator visible in the quote: one boy, one dose, one agent.
🔬

Diagnosis

2
Chromosomal Microarray
Detects the 12p12.1 and intragenic deletions, which is how the syndrome was originally defined. It will not detect the point variants that make up most of a contemporary cohort, nor a balanced translocation.
Show evidence (1 reference)
PMID:36861937 SUPPORT INDIRECT Human Clinical
"7/16 have intragenic deletions of SOX5 and 9/16 have single nucleotide variants (including both truncating and missense variants)."
Supports the limitation rather than the test: in this series a majority of lesions are point variants, which a microarray cannot see. INDIRECT because the inference from the mutational split to the test's sensitivity is the curator's.
SOX5 Sequencing
Detects the truncating and missense variants that a microarray misses, and is what a contemporary exome or gene panel does. In practice most diagnoses now arrive through broad sequencing rather than through a targeted test.
Show evidence (1 reference)
PMID:36861937 SUPPORT DIRECT Human Clinical
"We report 16 SOX5 variants all of which meet American College of Medical Genetics/Association for Clinical Genomic Science ACMG/ACGS criteria class IV or V."
Establishes that the sequence variants reported are classified pathogenic or likely pathogenic under a named standard, which is what makes a sequencing result actionable.
📊

Prevalence

1
Worldwide
Cases In Literature Ultra Rare
The 2019 spectrum-widening study described 41 novel patients against "just over two dozen" previously reported; a 2023 series added 16 more against 71 previously reported; and a 2023 Spanish cohort plus literature review reached 111. So the reported population has grown from roughly 25 to over a hundred across five years, which is a fact about ascertainment through exome sequencing and matchmaking rather than about incidence. No population rate is available.
Show evidence (4 references)
PMID:31578471 SUPPORT DIRECT Human Clinical
"Lamb-Shaffer syndrome (LAMSHF) is a neurodevelopmental disorder described in just over two dozen patients with heterozygous genetic alterations involving SOX5, a gene encoding a transcription factor regulating cell fate and differentiation in neurogenesis and other discrete developmental processes."
Gives the reported population at the time and, in the same sentence, the gene's normal role.
PMID:36861937 SUPPORT DIRECT Human Clinical
"This cohort of 16 patients is compared with the 71 previously reported cases and corroborates previous phenotypic findings."
The later count, which is what makes the growth of the reported population visible rather than having to be inferred.
PMID:37702321 SUPPORT DIRECT Human Clinical
"aracterization of a Spanish LSS cohort of new 20 patients and review all the patients published so far which amount for 111 patients."
The largest cumulative count available, from a cohort study that also performed the literature review. Quoted from mid-sentence because the cached abstract text begins the sentence with a truncated word.
+ 1 more reference
🐁

Animal Models

1
Sox5 null mouse
A constitutive Sox5 knockout, used to establish what the transcription factor does in corticogenesis rather than to model the human disease. It is the only in vivo system cited in this entry, and its relationship to the human lesion is a real limitation rather than a formality: the mouse is homozygous null and the patients are heterozygous.
Species
Mouse
Genotype
Sox5(-/-)
Publication
PMID:18215621
Pathograph links
Disrupted Neurodevelopmental Transcriptional Program partially recapitulates fidelity: moderate observes: cellular Identifies the programme SOX5 controls - temporal ordering of corticofugal neuron subtype generation - and shows what its loss does to that ordering.
Limitations: Sox5(-/-) is a homozygous null; the human disease is heterozygous haploinsufficiency, so the model tests whether SOX5 is required for the programme rather than whether halving it disturbs the programme. The readouts are neuronal subtype identity and timing in mouse cortex, not the clinical phenotypes this entry curates, and no behavioural or cognitive correspondence is claimed. Species divergence in cortical development is a further gap that the source does not address.
Divergences from the human mechanism
species mismatch qualifying
Mouse corticogenesis lacks the expanded outer subventricular zone and the human-specific progenitor populations that shape human cortical layering, so subtype-timing conclusions may not transfer directly.
scale extrapolation qualifying
The model observes neuronal subtype identity in cortex at the cellular level, while the node it is linked to is a tissue-level transcriptional programme, so the tissue claim is inferred from cellular readouts.
Readouts
Corticofugal neuron subtype identity
Direction: ALTERED
Interpretation: Overlapping rather than distinct subtype identities is the structural correlate of a mistimed generation programme.
Show evidence (1 reference)
PMID:18215621 SUPPORT DIRECT Model Organism
"SOX5 loss-of-function causes striking overlap of the identities of the three principal sequentially born corticofugal neuron subtypes: subplate neurons, corticothalamic neurons, and subcerebral projection neurons."
The measured outcome and its direction in the knockout.
Subtype-specific differentiation timing
Direction: ALTERED
Interpretation: Each of the three subtypes is affected differently, which is what distinguishes a timing defect from a general failure of differentiation.
Show evidence (1 reference)
PMID:18215621 SUPPORT DIRECT Model Organism
"In Sox5(-/-) cortex, subplate neurons aberrantly develop molecular hallmarks and connectivity of subcerebral projection neurons; corticothalamic neurons are imprecisely differentiated, while differentiation of subcerebral projection neurons is accelerated."
Resolves the phenotype per subtype, including an acceleration, which is the observation that makes "premature emergence" the right description.
Show evidence (1 reference)
PMID:18215621 SUPPORT INDIRECT Model Organism
"We report that the transcription factor SOX5 controls the sequential generation of distinct corticofugal neuron subtypes by preventing premature emergence of normally later-born corticofugal neurons."
Supports treating this model as informative for the node. INDIRECT: the study is about SOX5 biology in mouse and was not designed as a disease model, so its relevance to the human disorder is an inference.
{ }

Source YAML

click to show 
name: 12p12.1 Microdeletion Syndrome
creation_date: "2026-09-10T00:00:00Z"
category: Mendelian
description: >-
  The 12p12.1 microdeletion syndrome is the deletion form of Lamb-Shaffer syndrome, a
  neurodevelopmental disorder caused by haploinsufficiency of SOX5. The clinical picture is
  global developmental delay with disproportionately prominent speech delay, mild to
  moderate intellectual disability, behavioural features including autistic traits, and
  subtle characteristic facial features.

  The name is regional but the disease is not. Deletions at 12p12.1 were how the entity was
  found, but three other classes produce the same phenotype: intragenic deletions,
  truncating and missense point variants, and balanced translocations whose breakpoint
  falls inside SOX5. A translocation carries no copy-number change at all, and the affected
  individuals reported with one are clinically indistinguishable. Across the 83 variants
  reported up to 2023 the split is roughly even, 47 per cent single nucleotide variants
  against 53 per cent copy number variants, so neither class is a minority curiosity. The
  deleted region is not the disease-defining feature; loss of one functional SOX5 allele
  is, and this entry is curated on that basis with the deletion treated as one route to it.

  The strongest evidence that the region is not doing the work is that the smallest
  reported deletion narrows the critical interval to a segment containing SOX5 and nothing
  else.

  The missense variants are what make the haploinsufficiency claim more than an inference
  from gene dose. They cluster in the SOX-specific high-mobility-group domain, and the ones
  that do cluster there abolish DNA binding and transactivation in vitro, while missense
  variants elsewhere in the protein do neither and are generally better tolerated
  clinically. That is a structure-function-phenotype correspondence at three levels for one
  gene, and it is the strongest evidence in this entry.

  What is absent is equally worth stating: across a cohort of 41 patients no clear
  genotype-phenotype correlation was found beyond the tolerance of out-of-domain missense
  variants. Deletion size does not predict severity, and this entry therefore makes no
  claim that it does.
synonyms:
- Lamb-Shaffer syndrome
- LAMSHF
- SOX5 haploinsufficiency
- monosomy 12p12.1
- del(12)(p12.1)
disease_term:
  preferred_term: 12p12.1 microdeletion syndrome
  term:
    id: MONDO:0017781
    label: 12p12.1 microdeletion syndrome
parents:
- Neurodevelopmental Disorder
- Chromosomal Deletion Syndrome
classifications:
  harrisons_chapter:
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
    notes: >-
      A Mendelian dominant neurodevelopmental disorder, usually de novo, with
      transcription-factor haploinsufficiency as the mechanism.
  - classification_value: NEUROLOGIC
    notes: >-
      The clinical burden is developmental and behavioural, and the encounter is with
      developmental paediatrics and clinical genetics.
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0017781
      label: 12p12.1 microdeletion syndrome
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: >-
      The dismech entry and the MONDO class denote the same entity. The entry treats the
      concept as SOX5 haploinsufficiency rather than as a copy-number lesion, and records
      in notes that the MONDO label is narrower than the disease it names.
references:
- reference: PMID:29477873
  title: "Clinical and genetic characterization of a patient with SOX5 haploinsufficiency caused by a de novo balanced reciprocal translocation."
- reference: PMID:31578471
  title: "Widening of the genetic and clinical spectrum of Lamb-Shaffer syndrome, a neurodevelopmental disorder due to SOX5 haploinsufficiency."
- reference: PMID:36861937
  title: "SOX5: Lamb-Shaffer syndrome-A case series further expanding the phenotypic spectrum."
- reference: PMID:22290657
  title: "Haploinsufficiency of SOX5 at 12p12.1 is associated with developmental delays with prominent language delay, behavior problems, and mild dysmorphic features."
- reference: PMID:23220431
  title: "Haploinsufficiency of SOX5, a member of the SOX (SRY-related HMG-box) family of transcription factors is a cause of intellectual disability."
- reference: PMID:18215621
  title: "SOX5 controls the sequential generation of distinct corticofugal neuron subtypes."
- reference: PMID:37702321
  title: "Lamb-Shaffer syndrome: 20 Spanish patients and literature review expands the view of neurodevelopmental disorders caused by SOX5 haploinsufficiency."
- reference: PMID:39075495
  title: "Clinical cases series and pathogenesis of Lamb-Shaffer syndrome in China."
- reference: PMID:40180173
  title: "Optic atrophy in Lamb-Shaffer syndrome: two case presentations with ophthalmic imaging studies."
- reference: PMID:41531626
  title: "Risperidone-Induced Paradoxical Agitation in a Child With Lamb-Shaffer Syndrome, Autism Spectrum Disorder, and Attention Deficit Hyperactivity Disorder: A Case Report."
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    The 2019 spectrum-widening study described 41 novel patients against "just over two
    dozen" previously reported; a 2023 series added 16 more against 71 previously reported;
    and a 2023 Spanish cohort plus literature review reached 111. So the reported population
    has grown from roughly 25 to over a hundred across five years, which is a fact about
    ascertainment through exome sequencing and matchmaking rather than about incidence. No
    population rate is available.
  evidence:
  - reference: PMID:31578471
    reference_title: "Widening of the genetic and clinical spectrum of Lamb-Shaffer syndrome, a neurodevelopmental disorder due to SOX5 haploinsufficiency."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Lamb-Shaffer syndrome (LAMSHF) is a neurodevelopmental disorder described in just
      over two dozen patients with heterozygous genetic alterations involving SOX5, a gene
      encoding a transcription factor regulating cell fate and differentiation in
      neurogenesis and other discrete developmental processes.
    explanation: >-
      Gives the reported population at the time and, in the same sentence, the gene's
      normal role.
  - reference: PMID:36861937
    reference_title: "SOX5: Lamb-Shaffer syndrome-A case series further expanding the phenotypic spectrum."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "This cohort of 16 patients is compared with the 71 previously reported cases and corroborates previous phenotypic findings."
    explanation: >-
      The later count, which is what makes the growth of the reported population visible
      rather than having to be inferred.
  - reference: PMID:37702321
    reference_title: "Lamb-Shaffer syndrome: 20 Spanish patients and literature review expands the view of neurodevelopmental disorders caused by SOX5 haploinsufficiency."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      aracterization of a Spanish LSS cohort of new 20 patients and review all the patients
      published so far which amount for 111 patients.
    explanation: >-
      The largest cumulative count available, from a cohort study that also performed the
      literature review. Quoted from mid-sentence because the cached abstract text begins
      the sentence with a truncated word.
  - reference: PMID:39075495
    reference_title: "Clinical cases series and pathogenesis of Lamb-Shaffer syndrome in China."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "A total of 113 cases have been reported in the world, however, only 3 cases have been reported."
    explanation: >-
      An independent count reaching the same order, and one that also shows how uneven
      ascertainment is by country, which is the point the prevalence note makes.
pathophysiology:
- name: Loss of One Functional SOX5 Allele
  biological_scale: MOLECULAR
  mechanism_confidence: ESTABLISHED
  description: >-
    A heterozygous lesion that removes or disables one SOX5 allele. Four mutational classes
    are described and they converge here: microdeletions at 12p12.1, intragenic deletions,
    truncating and missense point variants, and balanced translocations with a breakpoint
    inside the gene. This node, rather than any one of those lesions, is what the entry is
    curated on.
  genetic_context:
    functional_impact_category: LOSS_OF_FUNCTION
    variant_origin: GERMLINE
    zygosity: HETEROZYGOUS
    gene:
      preferred_term: SOX5
      term:
        id: hgnc:11201
        label: SOX5
    description: >-
      Usually de novo. Parental gonadal mosaicism has been documented in at least one
      family, which matters for counselling: an apparently de novo variant does not
      guarantee a negligible recurrence risk.
  molecular_functions:
  - preferred_term: DNA-binding transcription factor activity
    modifier: DECREASED
    term:
      id: GO:0003700
      label: DNA-binding transcription factor activity
  evidence:
  - reference: PMID:31578471
    reference_title: "Widening of the genetic and clinical spectrum of Lamb-Shaffer syndrome, a neurodevelopmental disorder due to SOX5 haploinsufficiency."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Microdeletions and truncating variants occurred throughout SOX5."
    explanation: >-
      Establishes that the causal lesions are distributed across the gene rather than
      confined to the deleted region the syndrome is named after.
  - reference: PMID:29477873
    reference_title: "Clinical and genetic characterization of a patient with SOX5 haploinsufficiency caused by a de novo balanced reciprocal translocation."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Thus, the present patient has SOX5 haploinsufficiency affecting 2 long forms of SOX5
      and is the second reported case of Lamb-Shaffer syndrome caused by a de novo balanced
      reciprocal translocation.
    explanation: >-
      A patient with no copy-number change at all and the same disease, which is the
      observation that makes SOX5 dosage rather than the deleted interval the operative
      variable.
  - reference: PMID:23220431
    reference_title: "Haploinsufficiency of SOX5, a member of the SOX (SRY-related HMG-box) family of transcription factors is a cause of intellectual disability."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The smallest deletion helps to narrow down the critical region to a genomic segment
      (chr12:23,924,800-24,041,698, build 37/hg19) encompassing only one gene, SOX5.
    explanation: >-
      The strongest single statement that this is a one-gene disease rather than a
      contiguous-gene one. It reaches that conclusion from the deletion side, independently
      of the translocation case, by intersecting deletions of different sizes.
  - reference: PMID:22290657
    reference_title: "Haploinsufficiency of SOX5 at 12p12.1 is associated with developmental delays with prominent language delay, behavior problems, and mild dysmorphic features."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report one individual with a reciprocal translocation breakpoint within SOX5, eight
      individuals with intragenic SOX5 deletions (four are apparently de novo and one
      inherited from an affected parent), and seven individuals with larger 12p12 deletions
      encompassing SOX5.
    explanation: >-
      The founding series, and the one that establishes the point directly: three different
      lesion types, one phenotype. It is also where the disorder's eponym comes from.
  - reference: PMID:36861937
    reference_title: "SOX5: Lamb-Shaffer syndrome-A case series further expanding the phenotypic spectrum."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "7/16 have intragenic deletions of SOX5 and 9/16 have single nucleotide variants (including both truncating and missense variants)."
    explanation: >-
      Quantifies the mutational classes in one contemporary series. Read alongside the
      next item rather than alone: the larger cumulative count gives a roughly even split,
      so this series' majority of point variants should not be generalised.
  - reference: PMID:37702321
    reference_title: "Lamb-Shaffer syndrome: 20 Spanish patients and literature review expands the view of neurodevelopmental disorders caused by SOX5 haploinsufficiency."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Eighty-three variants have been reported so far, single nucleotide variants (SNV) and
      copy number variants represent 47% and 53%, respectively, from the total of variants
      reported.
    explanation: >-
      The better-powered mutational-class split, over 83 variants rather than 16. It points
      the opposite way from the 16-patient series and is the figure this entry relies on.
      Note that it does not weaken the lump/split decision, which rests on the critical
      region and the translocation rather than on a headcount.
  downstream:
  - target: Impaired SOX5 DNA Binding and Transactivation
    description: >-
      For the missense class the mechanism is directly demonstrated rather than inferred
      from dose: variants in the high-mobility-group domain abolish both DNA binding and
      transactivation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31578471
      reference_title: "Widening of the genetic and clinical spectrum of Lamb-Shaffer syndrome, a neurodevelopmental disorder due to SOX5 haploinsufficiency."
      supports: SUPPORT
      directness: DIRECT
      evidence_source: IN_VITRO
      snippet: >-
        The latter variants prevented SOX5 from binding DNA and promoting transactivation
        in vitro, whereas missense variants located outside the high-mobility-group domain
        did not.
      explanation: >-
        Both halves matter. The in-domain variants lose function, and the out-of-domain
        ones do not, which is an internal control that makes the assay interpretable.
- name: Impaired SOX5 DNA Binding and Transactivation
  biological_scale: MOLECULAR
  mechanism_confidence: ESTABLISHED
  description: >-
    SOX5 fails to bind its target DNA and to drive transcription. The functional lesion is
    localised to the SOX-specific high-mobility-group domain, which is where the
    disease-associated missense variants cluster.
  molecular_functions:
  - preferred_term: DNA-binding transcription factor activity
    modifier: LOSS_OF_FUNCTION
    term:
      id: GO:0003700
      label: DNA-binding transcription factor activity
  evidence:
  - reference: PMID:31578471
    reference_title: "Widening of the genetic and clinical spectrum of Lamb-Shaffer syndrome, a neurodevelopmental disorder due to SOX5 haploinsufficiency."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "In contrast, most missense variants clustered in the pivotal SOX-specific high-mobility-group domain."
    explanation: >-
      The clustering is what links the structural domain to disease causation in patients,
      independently of the in vitro assay.
  downstream:
  - target: Disrupted Neurodevelopmental Transcriptional Program
    description: >-
      SOX5 regulates cell fate and differentiation during neurogenesis; halving its
      effective activity perturbs that program.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31578471
      reference_title: "Widening of the genetic and clinical spectrum of Lamb-Shaffer syndrome, a neurodevelopmental disorder due to SOX5 haploinsufficiency."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Lamb-Shaffer syndrome (LAMSHF) is a neurodevelopmental disorder described in just
        over two dozen patients with heterozygous genetic alterations involving SOX5, a gene
        encoding a transcription factor regulating cell fate and differentiation in
        neurogenesis and other discrete developmental processes.
      explanation: >-
        States SOX5's normal role in neurogenesis. INDIRECT: the step from "regulates cell
        fate in neurogenesis" to "its partial loss disrupts the program in these patients"
        is an inference, and no source cited here measures the transcriptional program in
        patient neural tissue.
- name: Disrupted Neurodevelopmental Transcriptional Program
  biological_scale: TISSUE
  mechanism_confidence: PROVISIONAL
  description: >-
    The downstream transcriptional consequence in the developing nervous system. Mouse
    genetics gives this node real content rather than leaving it a placeholder: losing SOX5
    causes the three principal sequentially born corticofugal neuron subtypes to overlap in
    identity, because SOX5 normally prevents later-born subtypes from appearing early. So
    the program SOX5 controls is a temporal one, and the defect is mistiming of subtype
    generation rather than failure of neurogenesis as such.

    The node is PROVISIONAL rather than ESTABLISHED for a specific reason, not as a hedge.
    The mouse result comes from a homozygous null, and the human lesion is a heterozygous
    dosage reduction; whether halving SOX5 mistimes the same programme is not shown. Nor has
    the transcriptional programme been characterised in any patient-derived neural material.
    Those are two different gaps and the second is recorded separately.
  biological_processes:
  - preferred_term: central nervous system development
    modifier: DECREASED
    term:
      id: GO:0007417
      label: central nervous system development
  evidence:
  - reference: PMID:31578471
    reference_title: "Widening of the genetic and clinical spectrum of Lamb-Shaffer syndrome, a neurodevelopmental disorder due to SOX5 haploinsufficiency."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Lamb-Shaffer syndrome (LAMSHF) is a neurodevelopmental disorder described in just
      over two dozen patients with heterozygous genetic alterations involving SOX5, a gene
      encoding a transcription factor regulating cell fate and differentiation in
      neurogenesis and other discrete developmental processes.
    explanation: >-
      States SOX5's normal role in neurogenesis in the human-genetics literature.
  - reference: PMID:18215621
    reference_title: "SOX5 controls the sequential generation of distinct corticofugal neuron subtypes."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We report that the transcription factor SOX5 controls the sequential generation of
      distinct corticofugal neuron subtypes by preventing premature emergence of normally
      later-born corticofugal neurons.
    explanation: >-
      Identifies what the disrupted programme actually is: temporal control of corticofugal
      subtype generation. INDIRECT because the experiment is a mouse homozygous null and the
      human disease is a heterozygous dosage lesion, so the step to this node in humans is
      an inference across both species and zygosity.
  downstream:
  - target: Global Developmental Delay
    description: The clinical expression of the disrupted program.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:31578471
      reference_title: "Widening of the genetic and clinical spectrum of Lamb-Shaffer syndrome, a neurodevelopmental disorder due to SOX5 haploinsufficiency."
      supports: SUPPORT
      directness: DIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        This study extends the clinical and genetic spectrum associated with LAMSHF and
        consolidates evidence that SOX5 haploinsufficiency leads to variable degrees of
        intellectual disability, language delay, and other clinical features.
      explanation: >-
        States the gene-to-phenotype relationship. The intermediates between the
        transcriptional lesion and the clinical delay are not established, which the edge
        type records.
  - target: Delayed Speech and Language Development
    description: >-
      Speech delay is disproportionately prominent relative to the general developmental
      delay, which is the feature clinicians use to recognise the syndrome.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:36861937
      reference_title: "SOX5: Lamb-Shaffer syndrome-A case series further expanding the phenotypic spectrum."
      supports: SUPPORT
      directness: DIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        As expected, the most common findings include global developmental delay with
        prominent speech delay, mild to moderate intellectual disability, behavioral
        abnormalities and sometimes subtle characteristic facial features.
      explanation: >-
        Names speech delay as prominent within the general delay, in a series assembled
        specifically to corroborate the phenotype.
phenotypes:
- category: Neurologic
  name: Global Developmental Delay
  description: Developmental delay across domains, the presenting feature.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:36861937
    reference_title: "SOX5: Lamb-Shaffer syndrome-A case series further expanding the phenotypic spectrum."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      As expected, the most common findings include global developmental delay with
      prominent speech delay, mild to moderate intellectual disability, behavioral
      abnormalities and sometimes subtle characteristic facial features.
    explanation: Names global developmental delay as the most common finding.
- category: Neurologic
  name: Delayed Speech and Language Development
  description: >-
    Speech delay out of proportion to the general delay. The most clinically useful
    discriminating feature.
  phenotype_term:
    preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  evidence:
  - reference: PMID:31578471
    reference_title: "Widening of the genetic and clinical spectrum of Lamb-Shaffer syndrome, a neurodevelopmental disorder due to SOX5 haploinsufficiency."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This study extends the clinical and genetic spectrum associated with LAMSHF and
      consolidates evidence that SOX5 haploinsufficiency leads to variable degrees of
      intellectual disability, language delay, and other clinical features.
    explanation: Names language delay as a consolidated feature of the syndrome.
- category: Neurologic
  name: Intellectual Disability
  description: Mild to moderate intellectual disability, with variable degree.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:36861937
    reference_title: "SOX5: Lamb-Shaffer syndrome-A case series further expanding the phenotypic spectrum."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      As expected, the most common findings include global developmental delay with
      prominent speech delay, mild to moderate intellectual disability, behavioral
      abnormalities and sometimes subtle characteristic facial features.
    explanation: Gives both the finding and its usual severity band.
- category: Behavioral
  name: Autistic Behavior
  description: >-
    Autistic features are reported. The 2023 series expanded the behavioural description
    specifically, which is why this is curated as its own phenotype rather than folded into
    "behavioural abnormalities".
  phenotype_term:
    preferred_term: Autistic behavior
    term:
      id: HP:0000729
      label: Autistic behavior
  evidence:
  - reference: PMID:29477873
    reference_title: "Clinical and genetic characterization of a patient with SOX5 haploinsufficiency caused by a de novo balanced reciprocal translocation."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This report confirmed that haploinsufficiency of the 2 long forms of SOX5 presents
      common clinical features, including mild intellectual disability and autistic
      features, which could be useful for the clinical diagnosis of Lamb-Shaffer syndrome.
    explanation: >-
      Names autistic features among the common findings, in a patient ascertained through
      a translocation rather than a deletion.
- category: Growth
  name: Microcephaly
  description: >-
    Reported with an explicit genotype association: the 2023 series observed a greater
    tendency toward lower growth parameters and microcephaly in patients with single
    nucleotide variants than in those with deletions. That is the one genotype-phenotype
    signal in this entry, and it is described as a tendency in a 16-patient series rather
    than as an established correlation.
  phenotype_term:
    preferred_term: Microcephaly
    term:
      id: HP:0000252
      label: Microcephaly
  evidence:
  - reference: PMID:36861937
    reference_title: "SOX5: Lamb-Shaffer syndrome-A case series further expanding the phenotypic spectrum."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We expand in more detail on the behavioral phenotype and observe that there is a
      greater tendency toward lower growth parameters and microcephaly in patients with
      single nucleotide variants.
    explanation: >-
      Reports both the finding and the genotype class it is associated with. The authors'
      own hedge, "a greater tendency toward", is preserved rather than converted into a
      correlation claim.
- category: Ophthalmologic
  name: Ophthalmic Involvement
  description: >-
    Strabismus, refractive error and optic nerve abnormalities, reported in up to 57 per
    cent of patients. A majority-prevalence organ system, and the practical consequence is
    that ophthalmologic assessment belongs in the work-up.
  phenotype_term:
    preferred_term: Strabismus
    term:
      id: HP:0000486
      label: Strabismus
  frequency: FREQUENT
  evidence:
  - reference: PMID:40180173
    reference_title: "Optic atrophy in Lamb-Shaffer syndrome: two case presentations with ophthalmic imaging studies."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Up to 57% of patients have ophthalmic findings, including strabismus, refractive
      error, and optic nerve abnormalities.
    explanation: >-
      Gives both the frequency and the three component findings. Strabismus is bound as the
      HP term because it is the one named first and is the commonest; the other two are
      curated as their own phenotypes below.
  - reference: PMID:40163633
    reference_title: Bilateral Iris and Chorioretinal Colobomas in a Child With Suspected Lamb-Shaffer Syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Ophthalmic manifestations of LSS such as strabismus and optic nerve abnormalities have
      been described in approximately 55% of patients with LSS.
    explanation: >-
      An independent frequency estimate, 55 per cent against 57 per cent, which is close
      enough to treat the majority-prevalence claim as replicated rather than resting on one
      report.
- category: Ophthalmologic
  name: Abnormality of Refraction
  description: Refractive error, part of the ophthalmic cluster.
  phenotype_term:
    preferred_term: Abnormality of refraction
    term:
      id: HP:0000539
      label: Abnormality of refraction
  evidence:
  - reference: PMID:40180173
    reference_title: "Optic atrophy in Lamb-Shaffer syndrome: two case presentations with ophthalmic imaging studies."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Up to 57% of patients have ophthalmic findings, including strabismus, refractive
      error, and optic nerve abnormalities.
    explanation: Names refractive error among the ophthalmic findings.
- category: Ophthalmologic
  name: Optic Atrophy
  description: >-
    Optic nerve abnormality, documented with imaging in two siblings. Curated separately
    from the general ophthalmic cluster because it is a structural optic-nerve finding
    rather than a refractive or alignment one.
  phenotype_term:
    preferred_term: Optic atrophy
    term:
      id: HP:0000648
      label: Optic atrophy
  evidence:
  - reference: PMID:40180173
    reference_title: "Optic atrophy in Lamb-Shaffer syndrome: two case presentations with ophthalmic imaging studies."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We present 2 siblings who are the first documented cases of Lamb-Shaffer syndrome
      with the p.R571W: c.1711 C>T SOX5 mutation to demonstrate optic nerve atrophy.
    explanation: >-
      Two siblings, and the report says so - this is the first documentation of optic
      atrophy in the syndrome, so it should be read as a new and thinly evidenced finding
      rather than an established feature.
- category: Neurologic
  name: Seizures
  description: >-
    Seizures with EEG abnormalities, in 21 of 95 patients. Worth noting that the source
    reporting that fraction describes it as rare relative to the core features, so the
    entry does not present it as a cardinal feature.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:39075495
    reference_title: "Clinical cases series and pathogenesis of Lamb-Shaffer syndrome in China."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      erature and this study showed intellectual disability, speech delay and facial
      dysmorphisms were common clinical manifestation, while the seizures and EEG
      abnormalities were rare (21/95, 22
    explanation: >-
      Gives the fraction and the authors' own reading of it. The quote begins mid-word
      because the cached abstract text is truncated at that point, and ends before the
      decimal for the same reason; the denominator is what matters here.
- category: Craniofacial
  name: Facial Dysmorphism
  description: >-
    A recognisable but subtle facial gestalt: wide mouth with full lips, small chin, broad
    nasal bridge, deep-set eyes. Curated as a phenotype rather than left in prose so that it
    is queryable.
  phenotype_term:
    preferred_term: Abnormality of the face
    term:
      id: HP:0000271
      label: Abnormality of the face
  frequency: FREQUENT
  evidence:
  - reference: PMID:37702321
    reference_title: "Lamb-Shaffer syndrome: 20 Spanish patients and literature review expands the view of neurodevelopmental disorders caused by SOX5 haploinsufficiency."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additionally, patients with the syndrome may present distinct facial dimorphism such
      as a wide mouth with full lips, small chin, broad nasal bridge, and deep-set eyes.
    explanation: >-
      Enumerates the component features. Note the source's spelling, "dimorphism", is
      preserved as quoted rather than corrected.
  - reference: PMID:37702321
    reference_title: "Lamb-Shaffer syndrome: 20 Spanish patients and literature review expands the view of neurodevelopmental disorders caused by SOX5 haploinsufficiency."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most frequent features included developmental delay, intellectual disability,
      visual problems, poor speech development and facial dysmorphic features.
    explanation: >-
      Places facial dysmorphism among the most frequent features, which is what the
      FREQUENT band rests on.
- category: Neurologic
  name: Pain Insensitivity
  description: >-
    Reduced pain sensitivity, reported as more frequent than previously recognised. This is
    a recent observation from one cohort and is curated with that hedge; it is also
    clinically consequential, since a child who does not report pain can present late.
  phenotype_term:
    preferred_term: Pain insensitivity
    term:
      id: HP:0007021
      label: Pain insensitivity
  evidence:
  - reference: PMID:37702321
    reference_title: "Lamb-Shaffer syndrome: 20 Spanish patients and literature review expands the view of neurodevelopmental disorders caused by SOX5 haploinsufficiency."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Strikingly, pain insensitivity and hypermetropia seems to be more frequent than
      previously reported, based on the frequency seen in the Spanish cohort.
    explanation: >-
      Reports the finding with the authors' own framing - a frequency impression from one
      cohort, explicitly compared against prior reports rather than measured against a
      denominator - so no frequency band is asserted here.
- category: Ophthalmologic
  name: Hypermetropia
  description: >-
    Hypermetropia, reported in the same sentence as the pain insensitivity as apparently
    more frequent than earlier series suggested. Curated separately from the strabismus and
    optic-atrophy rows because it is a refractive error rather than a structural finding, and
    because its frequency claim rests on a different, weaker basis than theirs.
  phenotype_term:
    preferred_term: Hypermetropia
    term:
      id: HP:0000540
      label: Hypermetropia
  evidence:
  - reference: PMID:37702321
    reference_title: "Lamb-Shaffer syndrome: 20 Spanish patients and literature review expands the view of neurodevelopmental disorders caused by SOX5 haploinsufficiency."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Strikingly, pain insensitivity and hypermetropia seems to be more frequent than
      previously reported, based on the frequency seen in the Spanish cohort.
    explanation: >-
      Same sentence and same caveat as the pain-insensitivity row: a frequency impression
      from one cohort compared against prior reports, so no frequency band is asserted.
genetic:
- name: SOX5
  gene_term:
    preferred_term: SOX5
    term:
      id: hgnc:11201
      label: SOX5
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >-
    SRY-box transcription factor 5, a SOXD-family transcription factor regulating cell fate
    and differentiation in neurogenesis. The disease-relevant lesions affect the two long
    isoforms. Disease-associated missense variants cluster in the SOX-specific
    high-mobility-group domain and abolish DNA binding and transactivation; missense
    variants elsewhere do not and are better tolerated.
  evidence:
  - reference: PMID:31578471
    reference_title: "Widening of the genetic and clinical spectrum of Lamb-Shaffer syndrome, a neurodevelopmental disorder due to SOX5 haploinsufficiency."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: IN_VITRO
    snippet: >-
      The latter variants prevented SOX5 from binding DNA and promoting transactivation in
      vitro, whereas missense variants located outside the high-mobility-group domain did
      not.
    explanation: >-
      Functional demonstration for the missense class, with the out-of-domain variants
      serving as an internal negative control.
  - reference: PMID:29477873
    reference_title: "Clinical and genetic characterization of a patient with SOX5 haploinsufficiency caused by a de novo balanced reciprocal translocation."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We determined the translocation breakpoints of the patient to be in intron 4 of SOX5
      and the intergenic region in 20p12.3 via FISH and nucleotide sequence analyses.
    explanation: >-
      Localises a disease-causing breakpoint inside SOX5, which is what makes a balanced
      rearrangement an SOX5 lesion rather than a positional coincidence.
inheritance:
- name: Autosomal dominant
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >-
    Autosomal dominant, and in the great majority of reported cases de novo. Parental
    gonadal mosaicism has been documented, which is the counselling point: a couple with
    one affected child and an apparently de novo variant does not have a negligible
    recurrence risk.
  evidence:
  - reference: PMID:36861937
    reference_title: "SOX5: Lamb-Shaffer syndrome-A case series further expanding the phenotypic spectrum."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This cohort provides further evidence of gonadal mosaicism in SOX5 variants; this
      should be considered when providing genetic counseling for couples with one affected
      child and an apparently de novo variant.
    explanation: >-
      States both the observation and the counselling consequence the authors draw from it.
animal_models:
- name: Sox5 null mouse
  species: Mouse
  genotype: Sox5(-/-)
  publication: PMID:18215621
  description: >-
    A constitutive Sox5 knockout, used to establish what the transcription factor does in
    corticogenesis rather than to model the human disease. It is the only in vivo system
    cited in this entry, and its relationship to the human lesion is a real limitation
    rather than a formality: the mouse is homozygous null and the patients are heterozygous.
  modeled_mechanisms:
  - target: Disrupted Neurodevelopmental Transcriptional Program
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: CELLULAR
    description: >-
      Identifies the programme SOX5 controls - temporal ordering of corticofugal neuron
      subtype generation - and shows what its loss does to that ordering.
    limitations: >-
      Sox5(-/-) is a homozygous null; the human disease is heterozygous haploinsufficiency,
      so the model tests whether SOX5 is required for the programme rather than whether
      halving it disturbs the programme. The readouts are neuronal subtype identity and
      timing in mouse cortex, not the clinical phenotypes this entry curates, and no
      behavioural or cognitive correspondence is claimed. Species divergence in cortical
      development is a further gap that the source does not address.
    divergences:
    - divergence_type: SPECIES_MISMATCH
      materiality: QUALIFYING
      description: >-
        Mouse corticogenesis lacks the expanded outer subventricular zone and the
        human-specific progenitor populations that shape human cortical layering, so
        subtype-timing conclusions may not transfer directly.
    - divergence_type: SCALE_EXTRAPOLATION
      materiality: QUALIFYING
      description: >-
        The model observes neuronal subtype identity in cortex at the cellular level, while
        the node it is linked to is a tissue-level transcriptional programme, so the tissue
        claim is inferred from cellular readouts.
    readouts:
    - name: Corticofugal neuron subtype identity
      target: Disrupted Neurodevelopmental Transcriptional Program
      direction: ALTERED
      interpretation: >-
        Overlapping rather than distinct subtype identities is the structural correlate of
        a mistimed generation programme.
      evidence:
      - reference: PMID:18215621
        reference_title: "SOX5 controls the sequential generation of distinct corticofugal neuron subtypes."
        supports: SUPPORT
        directness: DIRECT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          SOX5 loss-of-function causes striking overlap of the identities of the three
          principal sequentially born corticofugal neuron subtypes: subplate neurons,
          corticothalamic neurons, and subcerebral projection neurons.
        explanation: The measured outcome and its direction in the knockout.
    - name: Subtype-specific differentiation timing
      target: Disrupted Neurodevelopmental Transcriptional Program
      direction: ALTERED
      interpretation: >-
        Each of the three subtypes is affected differently, which is what distinguishes a
        timing defect from a general failure of differentiation.
      evidence:
      - reference: PMID:18215621
        reference_title: "SOX5 controls the sequential generation of distinct corticofugal neuron subtypes."
        supports: SUPPORT
        directness: DIRECT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          In Sox5(-/-) cortex, subplate neurons aberrantly develop molecular hallmarks and
          connectivity of subcerebral projection neurons; corticothalamic neurons are
          imprecisely differentiated, while differentiation of subcerebral projection
          neurons is accelerated.
        explanation: >-
          Resolves the phenotype per subtype, including an acceleration, which is the
          observation that makes "premature emergence" the right description.
  evidence:
  - reference: PMID:18215621
    reference_title: "SOX5 controls the sequential generation of distinct corticofugal neuron subtypes."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We report that the transcription factor SOX5 controls the sequential generation of
      distinct corticofugal neuron subtypes by preventing premature emergence of normally
      later-born corticofugal neurons.
    explanation: >-
      Supports treating this model as informative for the node. INDIRECT: the study is about
      SOX5 biology in mouse and was not designed as a disease model, so its relevance to the
      human disorder is an inference.
treatments:
- name: Aripiprazole after Risperidone Intolerance
  description: >-
    Not a treatment recommendation, and it should not be read as one. A single reported
    child with Lamb-Shaffer syndrome developed paradoxical behavioural activation on very
    low-dose risperidone given for irritability and self-injury, and subsequently tolerated
    aripiprazole. It is curated because behavioural disturbance is a core part of this
    syndrome, psychotropic prescribing is therefore common, and this is the only
    disease-specific pharmacological observation in the literature - n=1, uncontrolled, and
    a paradoxical reaction to one agent in one child is not evidence about the class.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  therapeutic_modality: SMALL_MOLECULE
  evidence:
  - reference: PMID:41531626
    reference_title: "Risperidone-Induced Paradoxical Agitation in a Child With Lamb-Shaffer Syndrome, Autism Spectrum Disorder, and Attention Deficit Hyperactivity Disorder: A Case Report."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Data on psychotropic response profiles in Lamb-Shaffer syndrome are extremely limited.
    explanation: >-
      Curated as its own evidence item because it is the qualifier that governs how the
      efficacy observation should be read, and there is no slot for a strength qualifier on
      the item it qualifies.
  - reference: PMID:41531626
    reference_title: "Risperidone-Induced Paradoxical Agitation in a Child With Lamb-Shaffer Syndrome, Autism Spectrum Disorder, and Attention Deficit Hyperactivity Disorder: A Case Report."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report a six-year-five-month-old boy with de novo Lamb-Shaffer syndrome, autism
      spectrum disorder (ASD) of mild-to-moderate severity, attention deficit hyperactivity
      disorder, and query intellectual disability who developed paradoxical behavioral
      activation after initiation of very low-dose risperidone oral solution (0.12 mg once
      daily) for mild-to-moderate irritability, aggression, and self-injurious head banging.
    explanation: >-
      The observation itself, with its full denominator visible in the quote: one boy, one
      dose, one agent.
diagnosis:
- name: Chromosomal Microarray
  description: >-
    Detects the 12p12.1 and intragenic deletions, which is how the syndrome was originally
    defined. It will not detect the point variants that make up most of a contemporary
    cohort, nor a balanced translocation.
  evidence:
  - reference: PMID:36861937
    reference_title: "SOX5: Lamb-Shaffer syndrome-A case series further expanding the phenotypic spectrum."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "7/16 have intragenic deletions of SOX5 and 9/16 have single nucleotide variants (including both truncating and missense variants)."
    explanation: >-
      Supports the limitation rather than the test: in this series a majority of lesions
      are point variants, which a microarray cannot see. INDIRECT because the inference
      from the mutational split to the test's sensitivity is the curator's.
- name: SOX5 Sequencing
  description: >-
    Detects the truncating and missense variants that a microarray misses, and is what a
    contemporary exome or gene panel does. In practice most diagnoses now arrive through
    broad sequencing rather than through a targeted test.
  evidence:
  - reference: PMID:36861937
    reference_title: "SOX5: Lamb-Shaffer syndrome-A case series further expanding the phenotypic spectrum."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report 16 SOX5 variants all of which meet American College of Medical Genetics/Association for Clinical Genomic Science ACMG/ACGS criteria class IV or V."
    explanation: >-
      Establishes that the sequence variants reported are classified pathogenic or likely
      pathogenic under a named standard, which is what makes a sequencing result actionable.
discussions:
- discussion_id: no_disease_modifying_therapy
  kind: KNOWLEDGE_GAP
  attaches_to:
  - treatments#
  prompt: >-
    Is there any disease-modifying therapy for Lamb-Shaffer syndrome, or is management
    entirely symptomatic?
  rationale: >-
    The treatments section holds one row, and that row is a single-patient adverse-reaction
    report rather than a therapy. That thinness is a fact about the field rather than about
    the curation: the literature states plainly that no treatment exists. The gap is
    recorded so a reader does not mistake an almost-empty section for an unfinished one, and
    so that a future disease-modifying candidate has somewhere to attach.
  evidence:
  - reference: PMID:40163633
    reference_title: "Bilateral Iris and Chorioretinal Colobomas in a Child With Suspected Lamb-Shaffer Syndrome."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There is currently no treatment for LSS; however, robust understanding of LSS's
      heterogenous phenotypic and genetic profile will lead to improved knowledge of the
      syndrome and diagnostic aptitude.
    explanation: >-
      States the absence of treatment directly. Quoted with the authors' forward-looking
      second clause intact, because trimming at the semicolon would make the sentence read
      as more final than it is.
- discussion_id: entity_is_gene_not_region
  kind: KNOWLEDGE_GAP
  attaches_to:
  - disease#12p12.1 Microdeletion Syndrome
  - pathophysiology#Loss of One Functional SOX5 Allele
  prompt: >-
    Should this concept be named and modelled as a chromosomal microdeletion syndrome at
    all, given that most reported lesions are not deletions?
  rationale: >-
    MONDO:0017781 names a cytogenetic region and sits under "chromosome 12p deletion". The
    disease it labels is SOX5 haploinsufficiency, and in the most recent series nine of
    sixteen lesions were single nucleotide variants rather than deletions, while two
    reported patients have balanced translocations with no copy-number change at all. A
    region-named class implies that contiguous-gene effects matter, and nothing in the
    literature cited here suggests they do: no second gene in the interval has been
    implicated, and deletion size does not track severity. This entry is therefore curated
    as SOX5 haploinsufficiency with the deletion as one mutational class, and the mismatch
    between that and the MONDO label is recorded rather than papered over. It is an
    upstream question for MONDO whether Lamb-Shaffer syndrome should be the primary class.
  evidence:
  - reference: PMID:29477873
    reference_title: "Clinical and genetic characterization of a patient with SOX5 haploinsufficiency caused by a de novo balanced reciprocal translocation."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Thus, the present patient has SOX5 haploinsufficiency affecting 2 long forms of SOX5
      and is the second reported case of Lamb-Shaffer syndrome caused by a de novo balanced
      reciprocal translocation.
    explanation: >-
      A patient with the disease and no deletion. This is the single observation that most
      directly undercuts a region-based definition.
  - reference: PMID:23220431
    reference_title: "Haploinsufficiency of SOX5, a member of the SOX (SRY-related HMG-box) family of transcription factors is a cause of intellectual disability."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The smallest deletion helps to narrow down the critical region to a genomic segment
      (chr12:23,924,800-24,041,698, build 37/hg19) encompassing only one gene, SOX5.
    explanation: >-
      Settles the "no second gene in the interval" claim from the deletion side rather than
      by absence of evidence. Intersecting deletions of different sizes leaves a critical
      region containing SOX5 alone, which is what a contiguous-gene account would have to
      contradict.
- discussion_id: no_genotype_phenotype_correlation
  kind: KNOWLEDGE_GAP
  attaches_to:
  - pathophysiology#Loss of One Functional SOX5 Allele
  - phenotypes#Microcephaly
  prompt: >-
    Why is the clinical severity of SOX5 haploinsufficiency so variable when the molecular
    lesion is uniform, and does the microcephaly signal in point-variant patients survive a
    larger cohort?
  rationale: >-
    A 41-patient study found no clear genotype-phenotype correlation beyond the tolerance
    of out-of-domain missense variants, and severity nonetheless varies widely. Two
    readings are open. If the lesion really is uniform haploinsufficiency, the variability
    must come from modifiers or from the genetic background, and nothing has been done to
    look. Alternatively the lesions are not equivalent, and the later observation that
    point-variant patients tend toward lower growth parameters and microcephaly than
    deletion patients hints at that - which would be counterintuitive, since a whole-gene
    deletion is the more complete loss. That observation is a tendency in sixteen patients
    and needs replication before it is treated as a correlation. Until then this entry
    makes no claim that lesion class predicts severity.
  evidence:
  - reference: PMID:31578471
    reference_title: "Widening of the genetic and clinical spectrum of Lamb-Shaffer syndrome, a neurodevelopmental disorder due to SOX5 haploinsufficiency."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      No clear genotype-phenotype correlations were found, except that missense variants
      outside the high-mobility-group domain were generally better tolerated.
    explanation: >-
      The negative result this gap is built on, stated in the largest available cohort, with
      its one exception.
  - reference: PMID:31578471
    reference_title: "Widening of the genetic and clinical spectrum of Lamb-Shaffer syndrome, a neurodevelopmental disorder due to SOX5 haploinsufficiency."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical manifestations and severity varied among patients."
    explanation: States the variability that the absent correlation fails to explain.
- discussion_id: no_model_system
  kind: HUMAN_MODEL_MISMATCH
  attaches_to:
  - pathophysiology#Disrupted Neurodevelopmental Transcriptional Program
  - animal_models#Mouse
  prompt: >-
    Does halving SOXFive in a human brain mistime corticofugal subtype generation the way
    abolishing it does in a mouse?
  rationale: >-
    This is a mismatch rather than an absence, which is why it is typed
    HUMAN_MODEL_MISMATCH. Evidence exists and it is good: the Sox5 null mouse identifies the
    programme SOX5 controls and shows precisely how its loss disorders corticofugal subtype
    timing. What it cannot establish is the step this disease turns on. The mouse is a
    homozygous null and every reported patient is heterozygous, so the experiment answers
    "is SOX5 required" and the disease asks "what does half of it do". A dosage-sensitive
    transcription factor is exactly the case where those can come apart.

    Two further gaps sit alongside it and are genuinely absences. No patient-derived neural
    material has been transcriptionally characterised, so the human targets are unidentified.
    And mouse corticogenesis lacks the expanded outer subventricular zone that shapes human
    cortical layering, so even a heterozygous mouse would leave a species question open.

    Until that is addressed, the mechanism node stays PROVISIONAL and no therapeutic target
    follows from it.
  evidence:
  - reference: PMID:31578471
    reference_title: "Widening of the genetic and clinical spectrum of Lamb-Shaffer syndrome, a neurodevelopmental disorder due to SOX5 haploinsufficiency."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The present study was aimed at increasing our understanding of LAMSHF, its clinical
      and genetic spectrum, and the pathophysiological mechanisms involved.
    explanation: >-
      The largest study of the disorder states mechanism as an aim, and what it delivered
      on that aim was the in vitro DNA-binding result rather than anything in neural tissue.
      INDIRECT: this supports the gap by what the literature does not contain.
notes: >-
  Lump/split decision: DISEASE. MONDO:0017781 names one entity with one conserved
  pathograph, and the stub is retired accordingly. Its MONDO parent, chromosome 12p
  deletion (MONDO:0022174), is itself an uncurated open stub, so nothing here duplicates an
  existing entry.

  The entry is curated as SOX5 haploinsufficiency rather than as a copy-number lesion,
  and that is the substantive decision. Deletions at 12p12.1 are how the syndrome was
  found and gave it its name, but intragenic deletions, truncating and missense point
  variants and balanced translocations all produce the same disease, and in the most
  recent series point variants outnumber deletions. The root pathophysiology node is
  therefore "Loss of One Functional SOX5 Allele" and the deletion is one route to it. The
  mismatch between that model and the region-based MONDO label is recorded as its own
  knowledge gap rather than resolved here, since it is an upstream question.

  Lamb-Shaffer syndrome is carried as a synonym rather than as a separate concept. The
  literature uses the two names for one disease and has done since the deletions and the
  point variants were recognised as equivalent.

  One evidence-metadata limitation worth naming, because it shapes how this entry should
  be read. Almost every clinical statement here comes from a cohort, and the cohorts differ
  by an order of magnitude in size and by ascertainment route - 41 patients collected
  through GeneMatcher, 16 through a national database, a single translocation case report.
  dismech's EvidenceItem records the paper and the study type but not the sample size, so
  a reader cannot tell a 41-patient finding from a 1-patient one without opening the
  reference. This entry compensates by choosing snippets that carry their own denominators
  where such a sentence exists, which is why several quotes here include counts that a
  tidier summary sentence would have dropped.

  The treatments section carries one row and it is deliberately not a recommendation. There
  is no disease-modifying therapy and no published management guideline for this disorder.
  What does exist is a single case of paradoxical activation on low-dose risperidone with
  subsequent aripiprazole tolerance, which is curated because behavioural disturbance is
  core to the syndrome and psychotropic prescribing is therefore common. Its own source
  says data on psychotropic response in this syndrome are extremely limited, and that
  sentence is curated as its own evidence item so the qualifier travels with the claim.

  A note on how this entry was revised. The first version cited 3 of the 20 references its
  own deep-research run had fetched and committed, and review correctly identified that
  several of the uncited ones were the papers that would settle the entry's open questions.
  Two changed the content rather than merely padding it: the smallest-deletion critical
  region is a stronger argument for the single-gene reading than the translocation case
  alone, and the Sox5 null mouse supplies the mechanism the transcriptional-program node had
  been left holding open. A third corrected an overstatement - the first version generalised
  "point variants outnumber deletions" from a 16-patient series, and the 83-variant
  cumulative count is roughly even at 47 to 53 per cent. The lump/split decision is
  unchanged, and is now better supported.

  A correction to what the first round of this entry said about that review. It claimed the
  sentence "There is currently no treatment for LSS" is not in the cached text of
  PMID:40163633. It is, at the end of that abstract, and the claim was simply wrong. The
  sentence is now curated where it belongs, as evidence on the no_disease_modifying_therapy
  knowledge gap, rather than asserted in prose here. Recorded rather than deleted because a
  committed sentence asserting that a source lacks something outlives the session that wrote
  it, which is the failure check-source-defect-claims exists to catch and this phrasing
  happened to slip past.

  The deep-research report generated for this entry is committed alongside it under
  research/. Unlike the report for the KIDAR entry in the same run, it is on-target: it
  names SOX5 throughout and identifies Lamb-Shaffer syndrome correctly. Reference selection
  and every snippet here were nonetheless taken from the fetched reference cache rather
  than from the report.
📚

References & Deep Research

References

10
PMID:29477873
Clinical and genetic characterization of a patient with SOX5 haploinsufficiency caused by a de novo balanced reciprocal translocation.
No top-level findings curated for this source.
PMID:31578471
Widening of the genetic and clinical spectrum of Lamb-Shaffer syndrome, a neurodevelopmental disorder due to SOX5 haploinsufficiency.
No top-level findings curated for this source.
PMID:36861937
SOX5: Lamb-Shaffer syndrome-A case series further expanding the phenotypic spectrum.
No top-level findings curated for this source.
PMID:22290657
Haploinsufficiency of SOX5 at 12p12.1 is associated with developmental delays with prominent language delay, behavior problems, and mild dysmorphic features.
No top-level findings curated for this source.
PMID:23220431
Haploinsufficiency of SOX5, a member of the SOX (SRY-related HMG-box) family of transcription factors is a cause of intellectual disability.
No top-level findings curated for this source.
PMID:18215621
SOX5 controls the sequential generation of distinct corticofugal neuron subtypes.
No top-level findings curated for this source.
PMID:37702321
Lamb-Shaffer syndrome: 20 Spanish patients and literature review expands the view of neurodevelopmental disorders caused by SOX5 haploinsufficiency.
No top-level findings curated for this source.
PMID:39075495
Clinical cases series and pathogenesis of Lamb-Shaffer syndrome in China.
No top-level findings curated for this source.
PMID:40180173
Optic atrophy in Lamb-Shaffer syndrome: two case presentations with ophthalmic imaging studies.
No top-level findings curated for this source.
PMID:41531626
Risperidone-Induced Paradoxical Agitation in a Child With Lamb-Shaffer Syndrome, Autism Spectrum Disorder, and Attention Deficit Hyperactivity Disorder: A Case Report.
No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (3)

Record notes

Lump/split decision: DISEASE. MONDO:0017781 names one entity with one conserved pathograph, and the stub is retired accordingly. Its MONDO parent, chromosome 12p deletion (MONDO:0022174), is itself an uncurated open stub, so nothing here duplicates an existing entry. The entry is curated as SOX5 haploinsufficiency rather than as a copy-number lesion, and that is the substantive decision. Deletions at 12p12.1 are how the syndrome was found and gave it its name, but intragenic deletions, truncating and missense point variants and balanced translocations all produce the same disease, and in the most recent series point variants outnumber deletions. The root pathophysiology node is therefore "Loss of One Functional SOX5 Allele" and the deletion is one route to it. The mismatch between that model and the region-based MONDO label is recorded as its own knowledge gap rather than resolved here, since it is an upstream question. Lamb-Shaffer syndrome is carried as a synonym rather than as a separate concept. The literature uses the two names for one disease and has done since the deletions and the point variants were recognised as equivalent. One evidence-metadata limitation worth naming, because it shapes how this entry should be read. Almost every clinical statement here comes from a cohort, and the cohorts differ by an order of magnitude in size and by ascertainment route - 41 patients collected through GeneMatcher, 16 through a national database, a single translocation case report. dismech's EvidenceItem records the paper and the study type but not the sample size, so a reader cannot tell a 41-patient finding from a 1-patient one without opening the reference. This entry compensates by choosing snippets that carry their own denominators where such a sentence exists, which is why several quotes here include counts that a tidier summary sentence would have dropped. The treatments section carries one row and it is deliberately not a recommendation. There is no disease-modifying therapy and no published management guideline for this disorder. What does exist is a single case of paradoxical activation on low-dose risperidone with subsequent aripiprazole tolerance, which is curated because behavioural disturbance is core to the syndrome and psychotropic prescribing is therefore common. Its own source says data on psychotropic response in this syndrome are extremely limited, and that sentence is curated as its own evidence item so the qualifier travels with the claim. A note on how this entry was revised. The first version cited 3 of the 20 references its own deep-research run had fetched and committed, and review correctly identified that several of the uncited ones were the papers that would settle the entry's open questions. Two changed the content rather than merely padding it: the smallest-deletion critical region is a stronger argument for the single-gene reading than the translocation case alone, and the Sox5 null mouse supplies the mechanism the transcriptional-program node had been left holding open. A third corrected an overstatement - the first version generalised "point variants outnumber deletions" from a 16-patient series, and the 83-variant cumulative count is roughly even at 47 to 53 per cent. The lump/split decision is unchanged, and is now better supported. A correction to what the first round of this entry said about that review. It claimed the sentence "There is currently no treatment for LSS" is not in the cached text of PMID:40163633. It is, at the end of that abstract, and the claim was simply wrong. The sentence is now curated where it belongs, as evidence on the no_disease_modifying_therapy knowledge gap, rather than asserted in prose here. Recorded rather than deleted because a committed sentence asserting that a source lacks something outlives the session that wrote it, which is the failure check-source-defect-claims exists to catch and this phrasing happened to slip past. The deep-research report generated for this entry is committed alongside it under research/. Unlike the report for the KIDAR entry in the same run, it is on-target: it names SOX5 throughout and identifies Lamb-Shaffer syndrome correctly. Reference selection and every snippet here were nonetheless taken from the fetched reference cache rather than from the report.

Review round 2: fix snippet-grading divergence, correct a wrong claim about the cache · 2026-09-10T18:17:02Z · View source

Round 2 of review on PR #11619. Two blocking items and one suggestion, in one push. CRITICAL, check-snippet-grading. The same PMID:31578471 sentence was graded HUMAN_CLINICAL at prevalence[0] and OTHER at two pathophysiology sites. The reviewer is right that evidence_source classifies the cited publication and so cannot change because the quote moved. Both occurrences are now HUMAN_CLINICAL. The inference nuance the OTHER grade was reaching for is already carried by directness: INDIRECT on both items, which is the axis for it, so nothing is lost. The gate now exits clean. IMPORTANT, a wrong claim about repository state. The notes: section asserted that the sentence 'There is currently no treatment for LSS' is not in the cached text of PMID:40163633. It is, at the end of that abstract. The assertion was wrong and is removed. The sentence is now curated as evidence on a new no_disease_modifying_therapy KNOWLEDGE_GAP attached to treatments#, which is a better home than prose: the treatments section holds one adverse-reaction row and a reader should be able to see that the thinness is a fact about the field. The correction is recorded in notes rather than silently deleted, because a committed sentence claiming a source is defective outlives the session that wrote it and check-source-defect-claims did not fire on this phrasing. While curating that evidence item I wrote its reference_title from having read the abstract rather than copying the cache frontmatter, and produced 'Colobomas and Lens Subluxation as Possible Additional Ophthalmic Manifestations of Lamb-Shaffer Syndrome' for a paper actually titled 'Bilateral Iris and Chorioretinal Colobomas in a Child With Suspected Lamb-Shaffer Syndrome'. The reference validator caught it. This is the exact failure CLAUDE.md documents for citation strings and it is worth recording that it recurred inside the very edit that was correcting a different claim about the same file. SUGGESTION taken: hypermetropia added as its own ophthalmologic phenotype, from the second finding sitting inside the pain-insensitivity sentence. It is kept separate from the strabismus and optic-atrophy rows because it is a refractive rather than structural finding and its frequency claim rests on a weaker basis, which the explanation says. SUGGESTION declined: gnomAD constraint metrics. They appear in the deep-research report but no cached reference carries them as a quotable sentence, and CLAUDE.md forbids writing numbers from a report rather than from a source. A ClinGen dosage-sensitivity record for SOX5 would be the right citable substitute, but just clingen-dosage-refresh currently fails on a checksum drift against the unversioned upstream file, and repinning a manifest belongs in its own PR with its cache diff rather than inside a curation change. SUGGESTION declined: renaming discussion_id no_model_system. The reviewer agreed the rename costs an entity-ref sweep for no functional gain. Validation: schema clean, terms clean, 47 of 47 snippets verified, and check-snippet-grading, entity refs, duplicate keys, causal targets, enum values and qualifier terms all clean.

Review round 1: consume the cached references, add the mouse model, correct the mutational-class claim · 2026-09-10T17:41:06Z · View source

Response to ai4c-reviewer changes-requested on PR #11619. The blocking finding was correct: the first version cited 3 of the 20 references its own deep-research run had fetched and committed, and several uncited ones bore directly on the entry's open questions. Changes: (1) cite PMID:23220431, whose smallest-deletion critical region contains SOX5 alone and settles the single-gene claim from the deletion side, on the root node and the entity_is_gene_not_region discussion; (2) cite PMID:22290657, the founding series and eponym source; (3) add an animal_models entry for the Sox5 null mouse (PMID:18215621) with modeled_mechanisms, two readouts, and typed SPECIES_MISMATCH and SCALE_EXTRAPOLATION divergences, move the transcriptional-program node from HYPOTHETICAL to PROVISIONAL, and retype the no_model_system gap to HUMAN_MODEL_MISMATCH since the mouse is a homozygous null against a human heterozygous lesion, which is a mismatch rather than an absence; (4) add seven phenotypes with cached evidence: ophthalmic involvement (~57%), refraction, optic atrophy, seizures (21/95), facial dysmorphism, pain insensitivity; (5) correct an overstatement of my own, that point variants outnumber deletions, generalised from a 16-patient series, against the 83-variant cumulative 47/53 split; (6) update prevalence to 111 reported patients; (7) add the risperidone paradoxical-agitation case as a hedged treatment row with its own limited-data qualifier as a separate evidence item; (8) genetic review_notes moved to notes. NOT adopted: the review attributed 'There is currently no treatment for LSS' to PMID:40163633 and that sentence is not in the cached text; stated in prose instead. Re-validated: 45/45 snippets verified (was 25/25), terms, entity-refs, duplicate-keys, causal-targets, enum-values, qualifier-terms all pass.

OpenScientist ▸
12p12.1 Microdeletion Syndrome (Lamb–Shaffer Syndrome): A Comprehensive Disease Characteristics Report
openscientist-autonomous 19 citations 2026-09-10T17:15:13.006300

12p12.1 Microdeletion Syndrome (Lamb–Shaffer Syndrome): A Comprehensive Disease Characteristics Report

MONDO ID: MONDO:0017781 · OMIM: #616803 (LAMSHF) · Causal gene: SOX5 (12p12.1) · Category: Mendelian, autosomal dominant

Summary

12p12.1 microdeletion syndrome is a rare autosomal-dominant neurodevelopmental disorder caused by haploinsufficiency of the transcription-factor gene SOX5, and it is synonymous with Lamb–Shaffer syndrome (LAMSHF; OMIM #616803; MONDO:0017781). The critical region on chromosome 12p12.1 was narrowed to a single gene — SOX5 — establishing that loss of one functional copy of this SRY-related HMG-box transcription factor is both necessary and sufficient to produce the syndrome. The disorder was first delineated by Lamb et al. (2012) in 16 individuals and refined by Schanze et al. (2013), who used a 120 kb minimal deletion encompassing only SOX5 to pinpoint the causal gene.

The core clinical picture is a neurodevelopmental one: near-universal global developmental delay and intellectual disability, prominent expressive speech/language delay, motor delay, and behavioral abnormalities (attention-deficit/hyperactivity disorder, autism-spectrum traits). Additional recurrent features include mild facial dysmorphism, ophthalmic abnormalities (strabismus, refractive error/hypermetropia, optic-nerve atrophy, occasionally colobomas) in roughly 55–57% of patients, musculoskeletal features (scoliosis, joint hypermobility, short stature), seizures in a minority, and reported pain insensitivity. Mechanistically, the pleiotropy is explained by SOX5's multiple developmental roles: it controls the timed sequential generation of corticofugal neuron subtypes in the developing cortex, cooperates with SOX6/SOX9 in chondrogenesis, and serves as a DNA-binding cofactor for BMP receptor-Smads and in neural-crest/pigment-cell fate specification.

The loss-of-function mechanism is independently corroborated by four evidence streams: human clinical genetics (de novo microdeletions, truncating variants, and HMG-domain missense variants that abolish DNA binding and transactivation), model-organism biology (mouse Sox5 knockouts show corticofugal identity defects; Sox5;Sox6 double-nulls die of chondrodysplasia), in vitro functional assays, and computational constraint metrics (gnomAD pLI = 1.00, LOEUF = 0.17, placing SOX5 among the most loss-of-function-intolerant genes in the genome). The disorder is mostly de novo, with rare inheritance from an affected parent and documented parental gonadal mosaicism affecting recurrence risk. Diagnosis is by chromosomal microarray or exome sequencing; management is entirely supportive, as no disease-specific or curative therapy exists.

1. Disease Information

Overview. 12p12.1 microdeletion syndrome is a rare Mendelian neurodevelopmental disorder resulting from a heterozygous deletion (or functionally equivalent disruption) of the SOX5 gene at chromosome band 12p12.1. It is clinically and genetically synonymous with Lamb–Shaffer syndrome (LAMSHF). Rather than being a contiguous-gene deletion syndrome with many dosage-sensitive genes, this condition is fundamentally a single-gene (SOX5) haploinsufficiency disorder — larger 12p12 deletions, intragenic deletions, truncating point mutations, splice variants, HMG-domain missense variants, and balanced translocations disrupting SOX5 all converge on the same phenotype.

Key identifiers.

Resource Identifier
MONDO MONDO:0017781
OMIM #616803 (Lamb–Shaffer syndrome, LAMSHF)
Gene OMIM SOX5 604975
HGNC 11201 (SOX5)
Ensembl ENSG00000134532
NCBI Gene (Entrez) 6660
Cytogenetic locus 12p12.1

Synonyms / alternative names: Lamb–Shaffer syndrome; LAMSHF; SOX5 haploinsufficiency syndrome; SOX5-related intellectual disability/neurodevelopmental disorder; 12p12.1 deletion syndrome.

Data source type. The evidence base is derived predominantly from aggregated, disease-level resources — published case series and cohort studies pooling individually reported patients (>110 cases in the literature as of 2023–2024), combined with model-organism and in-vitro functional data, rather than from a single EHR-based population dataset.

2. Etiology

Primary causal factor — genetic. The disorder is caused by haploinsufficiency of SOX5 — i.e., reduction of functional SOX5 dosage to ~50% of normal. Lamb et al. (2012) concluded that "SOX5 appears to be a dosage-sensitive, developmentally important gene" [PMID: 22290657]. Schanze et al. (2013) narrowed the critical region: "The smallest deletion helps to narrow down the critical region to a genomic segment (chr12:23,924,800-24,041,698, build 37/hg19) encompassing only one gene, SOX5" [PMID: 23220431].

Genetic risk factors. The syndrome is monogenic; the "risk factor" is simply the presence of a heterozygous loss-of-function SOX5 lesion. There are no established polygenic susceptibility loci or modifier genes with proven effect on penetrance/severity. No clear genotype–phenotype severity correlation has been established (Zawerton et al. 2020), though the molecular pathogenicity of variants is domain-dependent (see §4).

Environmental risk factors / protective factors. None identified. Because the condition arises from a discrete germline structural or sequence lesion — most often de novo — there are no known environmental, lifestyle, dietary, occupational, or infectious risk or protective factors, and no established gene–environment interactions. Advanced parental age is a general (non-specific) consideration for de novo mutation but has not been specifically quantified for SOX5.

Gene–environment interactions. Not applicable / none documented.

3. Phenotypes

The phenotype is a neurodevelopmental syndrome with variable multisystem involvement. Frequencies below are pooled from the largest cohorts: Tenorio-Castaño 2023 (20 new + 111 total; PMID: 37702321), Edgerley 2023 (PMID: 36861937), Zawerton 2020 (41 patients; PMID: 31578471), Lian 2024 China (PMID: 39075495), and ophthalmic series (PMID: 40180173).

Phenotype Type HPO suggestion Frequency Onset / course
Global developmental delay / intellectual disability Cognitive HP:0001263 / HP:0001249 Near-universal Congenital/infantile; stable-static
Expressive speech & language delay (prominent) Cognitive/behavioral HP:0000750 / HP:0002463 Very high (hallmark) Early childhood
Motor delay Neuromotor HP:0001270 High Infantile
Behavioral abnormalities (ADHD, ASD traits) Behavioral HP:0000708 / HP:0007018 / HP:0000717 High Childhood
Ophthalmic anomalies (strabismus, refractive error/hypermetropia, optic-nerve atrophy, colobomas) Clinical sign HP:0000486 / HP:0000539 / HP:0000648 / HP:0000589 ~55–57% Childhood
Facial dysmorphism (wide mouth/full lips, small chin, broad nasal bridge, deep-set eyes) Physical HP:0000271 / HP:0000322 Common (mild) Congenital
Scoliosis Skeletal HP:0002650 Variable Childhood; may progress
Joint hypermobility Musculoskeletal HP:0001382 Variable Childhood
Short stature Growth HP:0004322 Variable Childhood
Seizures / EEG abnormalities Neurological HP:0001250 ~22% (21/95, Lian 2024) Variable
Pain insensitivity Sensory HP:0007021 Reported, possibly under-recognized —
Hypotonia Neuromuscular HP:0001252 Common Infantile

Tenorio-Castaño et al. summarized the frequency ranking: "The most frequent features included developmental delay, intellectual disability, visual problems, poor speech development and facial dysmorphic features. Strikingly, pain insensitivity and hypermetropia seems to be more frequent than previously reported" [PMID: 37702321]. The ophthalmic burden is substantial: "Up to 57% of patients have ophthalmic findings, including strabismus, refractive error, and optic nerve abnormalities" [PMID: 40180173].

Severity / progression. Intellectual disability is typically mild-to-moderate and static (non-progressive/non-degenerative). Skeletal features such as scoliosis may progress during growth. Quality-of-life impact is driven chiefly by the speech/language and cognitive impairment (affecting communication, education, independence) and behavioral features; formal EQ-5D/SF-36/PROMIS data specific to LAMSHF are not available in the literature.

4. Genetic / Molecular Information

Causal gene. SOX5 (SRY-Box Transcription Factor 5; HGNC:11201; OMIM 604975; ENSG00000134532; Entrez 6660), located on chromosome 12p12.1, minus strand, spanning approximately chr12:23,529,500–23,951,032 (GRCh38). SOX5 is a member of the SOXD subfamily and functions, in its long form (L-Sox5), as a transcription factor that binds DNA via a SOX-specific HMG-box domain and dimerizes to bind DNA cooperatively.

Pathogenic variant spectrum. All variant classes reduce SOX5 dosage/function: - Structural / copy-number: larger 12p12 deletions, intragenic SOX5 deletions, and balanced reciprocal translocations disrupting SOX5 (e.g., t(12;20)(p12.1;p12.3) with breakpoint in intron 4; PMID: 29477873). - Truncating: nonsense and frameshift variants throughout the gene (e.g., c.1477C>T/p.R493, c.290delC/p.Pro97fs30, c.1411C>T/p.Arg471). - Splice-site: e.g., c.1772-1C>A, validated by minigene assay to produce a truncated protein (Lian 2024). - Missense:* cluster in the HMG domain.

Variant classification & functional mechanism. Zawerton et al. (2020), studying 41 novel patients, established the key genotype–function relationship: "most missense variants clustered in the pivotal SOX-specific high-mobility-group domain. The latter variants prevented SOX5 from binding DNA and promoting transactivation in vitro, whereas missense variants located outside the high-mobility-group domain did not" [PMID: 31578471]. Thus HMG-domain missense variants are pathogenic loss-of-function (abolishing DNA binding/transactivation), whereas non-HMG missense variants are generally better tolerated. Truncating and structural variants act by classical haploinsufficiency (loss of function).

Functional consequence: Loss of function / haploinsufficiency (not gain-of-function or dominant-negative for the deletions/truncations; HMG missense are functionally null for DNA binding).

Allele frequency. Pathogenic variants are private/de novo and essentially absent from population databases (gnomAD, 1000 Genomes). SOX5 itself is strongly depleted of loss-of-function variants in gnomAD (see §6/constraint below).

Origin: Germline. Somatic mosaicism is relevant only in the context of parental gonadal mosaicism (see §9).

Modifier genes / epigenetics. No validated modifier genes are established for LAMSHF. No disease-specific DNA-methylation "episignature" has been reported to date (unlike some other chromatin-related NDDs). Notably, Sox5 is itself a downstream target dysregulated in models of other chromatin disorders (e.g., misexpressed in Gatad2b haploinsufficient mouse cortex; PMID: 38238293), positioning it within NuRD-regulated neurodevelopmental transcriptional programs.

Chromosomal abnormalities. The defining lesion is a 12p12.1 microdeletion; balanced translocations disrupting SOX5 produce the same phenotype, confirming that gene disruption (not deletion of neighboring genes) is the operative mechanism.

5. Environmental Information

Not applicable. No environmental toxins, radiation, pollution, occupational exposures, lifestyle/behavioral factors, or infectious agents are known to cause, trigger, or modify 12p12.1 microdeletion / Lamb–Shaffer syndrome. It is a purely genetic (predominantly de novo germline) disorder.

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation)

  1. A heterozygous loss-of-function lesion in SOX5 (microdeletion, truncating/splice variant, HMG-domain missense variant, or translocation) reduces functional SOX5 protein to ~50% of normal (haploinsufficiency). [demonstrated — human genetics + gnomAD constraint]
  2. Reduced SOX5 dosage leads to insufficient SOX5-dependent transcriptional regulation at target loci, because SOX5 acts as a DNA-binding transcription factor and as a cofactor that recruits partner factors (e.g., BMP R-Smads) to regulatory elements. [demonstrated in vitro; PMID 25453832]
  3. Branch A (cortical neurodevelopment): Insufficient SOX5 results in loss of the temporal "brake" on corticofugal neuron subtype generation → premature/overlapping emergence of subplate, corticothalamic, and subcerebral projection-neuron identities → imprecise laminar/cortical wiring. [demonstrated in mouse; PMID 18215621] → leads to intellectual disability, speech/language delay, and behavioral abnormalities. [inferred causal link between mouse cellular defect and human cognition]
  4. Branch B (skeletal/cartilage): Reduced SOX5 weakens the SOX5–SOX6–SOX9 cooperative activation of cartilage-matrix genes (Col2a1, aggrecan) → milder/sub-threshold chondrogenesis defects. [demonstrated in mouse/in vitro; PMIDs 11702786, 11680692] → contributes to scoliosis, joint hypermobility, and short stature. [inferred]
  5. Branch C (neural crest / BMP patterning): Reduced SOX5 impairs its cofactor role for BMP R-Smads and neural-crest gene regulation → subtle craniofacial/ectodermal and pigment-lineage effects. [demonstrated in Xenopus/fish; PMIDs 25453832, 24699463, 28012818] → may contribute to facial dysmorphism and ophthalmic (including neural-crest-derived ocular) anomalies. [inferred / speculative for the ophthalmic branch]

Detail by category

Molecular pathways. (i) SOX-family transcriptional control of neuronal subtype specification (Branch A). (ii) BMP/SMAD signaling — Sox5 is a DNA-binding cofactor for BMP R-Smads: "Sox5 is essential for activation of BMP target genes in embryos and explants, that it physically interacts with BMP R-Smads, and that it is essential for recruitment of Smad1/4 to BMP regulatory elements" [PMID: 25453832]. (iii) SOX5/6/9 cooperative activation of chondrogenic enhancers: "The transcription factors L-Sox5, Sox6, and Sox9 bound and cooperatively activated this enhancer in vitro" [PMID: 11680692].

Cellular processes. Regulation of the timing of neuronal differentiation (a cell-fate/temporal-identity process rather than apoptosis-driven), chondrocyte differentiation, and neural-crest fate specification. In mouse, "SOX5 loss-of-function causes striking overlap of the identities of the three principal sequentially born corticofugal neuron subtypes: subplate neurons, corticothalamic neurons, and subcerebral projection neurons" [PMID: 18215621], and "the transcription factor SOX5 controls the sequential generation of distinct corticofugal neuron subtypes by preventing premature emergence of normally later-born corticofugal neurons" [PMID: 18215621].

Protein dysfunction. Loss of function via reduced protein quantity (deletions/truncations) or abolished DNA-binding capacity (HMG-domain missense). No aggregation/misfolding gain-of-function mechanism.

Metabolic / immune / tissue-damage / biochemical. Not implicated as primary mechanisms; this is a developmental transcription-factor disorder, not a metabolic, immune, or degenerative one.

Epigenetic. SOX5 operates within developmental gene-regulatory networks and is a downstream target of chromatin remodelers (NuRD/GATAD2B; PMID: 38238293), but no LAMSHF-specific methylation signature is established.

Molecular profiling. GTEx v8 shows SOX5 is broadly but modestly expressed in adult tissues — highest in testis (~15.3 TPM), tibial artery (~8.5), cervix (~7.2), tibial nerve (~6.7), subcutaneous adipose (~5.1); adult brain subregions moderate (~2.3 TPM median across 13 regions); lowest in whole blood (~0.02 TPM). This adult expression pattern underscores that the pathogenic action is developmental (embryonic corticogenesis, chondrogenesis, neural crest), not adult-steady-state.

Suggested ontology terms. GO:0021895 (cerebral cortex neuron differentiation); GO:0030509 (BMP signaling pathway); GO:0051216 (cartilage development); GO:0014032 (neural crest cell development); GO:0006357 (regulation of transcription by RNA Pol II); GO:0003700 (DNA-binding transcription factor activity). CL:0000679-family corticofugal projection neurons; CL:0000138 (chondrocyte); CL:0000333 (neural crest cell); CL:0000148 (melanocyte).

7. Anatomical Structures Affected

Organ / system level (primary): Central nervous system — cerebral cortex (UBERON:0000956), especially deep-layer corticofugal projection neurons and cortical circuitry. Body systems: nervous (primary); musculoskeletal/skeletal (scoliosis, joints, stature); visual system/eye (UBERON:0000970) — strabismus, optic nerve (UBERON:0000941) atrophy, retina/iris colobomas; craniofacial skeleton (dysmorphism).

Secondary involvement: Occasional cardiac and genitourinary defects have been reported in broader phenotype descriptions (PMID: 40163633).

Tissue / cell level: Nervous tissue — corticofugal projection neurons (subplate, corticothalamic, subcerebral). Cartilage/connective tissue — chondrocytes (CL:0000138). Neural-crest-derived tissues — including pigment/melanocyte lineage and craniofacial mesenchyme (CL:0000333, CL:0000148).

Subcellular level: Nucleus (GO:0005634) — site of SOX5 transcription-factor action (sequence-specific DNA binding via HMG-box).

Localization / lateralization: CNS involvement is bilateral/global; ophthalmic and skeletal findings may be bilateral (e.g., bilateral optic atrophy, bilateral colobomas) or asymmetric.

8. Temporal Development

Onset. Congenital in origin (germline lesion); clinical recognition is typically in infancy to early childhood, prompted by developmental delay, hypotonia, and speech delay. Onset pattern is chronic/static (a developmental, non-degenerative course).

Progression. Cognitive impairment is generally stable/static rather than progressive. Some features may evolve with growth — e.g., scoliosis can progress; behavioral phenotypes (ADHD/ASD) become more apparent in childhood; ophthalmic issues may require ongoing management. Disease duration is lifelong.

Patterns / critical periods. The mechanistically critical window is embryonic/fetal neurodevelopment (cortical neurogenesis and neuronal subtype specification) — the period during which SOX5 dosage matters most — which is inaccessible to postnatal intervention. Postnatally, early childhood is the key window for developmental, speech, and behavioral intervention. No spontaneous remission occurs.

9. Inheritance and Population

Inheritance. Autosomal dominant. Most cases are de novo: Lamb et al. reported "eight individuals with intragenic SOX5 deletions (four are apparently de novo and one inherited from an affected parent)" [PMID: 22290657], and Schanze et al. confirmed de novo occurrence where parental samples were available. Rare inheritance from an affected parent occurs (consistent with AD transmission).

Penetrance / expressivity. Penetrance appears high/complete for developmental phenotypes, with variable expressivity (variable severity and organ involvement across individuals sharing similar or identical variants — e.g., differing features among unrelated patients with the recurrent p.R493* variant). No genetic anticipation (not a repeat-expansion disorder).

Germline (gonadal) mosaicism. Documented and clinically important for recurrence-risk counseling: Edgerley et al. state their "cohort provides further evidence of gonadal mosaicism in SOX5 variants; this should be considered when providing" genetic counseling [PMID: 36861937]. Monozygotic twin pairs concordant for the condition have also been reported.

Founder effects / consanguinity / carrier frequency. Not applicable — de novo dominant lesions; no founder alleles, no consanguinity role, and no meaningful population carrier frequency.

Epidemiology. Rare; precise prevalence/incidence are not established. More than 110–113 cases had been reported in the literature by 2023–2024 (Tenorio-Castaño 2023; Lian 2024). No strong ethnic predilection (cases reported worldwide, including expanding Asian cohorts). Sex ratio is not clearly skewed. Age distribution of reported patients is predominantly pediatric, reflecting ascertainment.

Constraint metric (population genomics). gnomAD (GRCh38) constraint for SOX5 quantitatively confirms extreme intolerance to haploinsufficiency: pLI = 1.00, observed/expected LoF (oe_lof) = 0.098 (90% CI 0.059–0.171; LOEUF = 0.17), LoF Z = 7.34, missense Z = 4.20 (significant missense constraint), synonymous Z ≈ −0.25 (neutral). A LOEUF < 0.35 with pLI ≈ 1 places SOX5 among the most loss-of-function-intolerant genes in the genome — an orthogonal, population-scale confirmation of the haploinsufficiency mechanism.

10. Diagnostics

Recommended approach. Diagnosis is genetic. Because the causal lesions span copy-number and sequence variants, the first-line tests are: - Chromosomal microarray (CMA) — detects 12p12.1 microdeletions and intragenic SOX5 deletions (historically how many cases were found). - Exome sequencing (WES) / whole-genome sequencing (WGS) — detects truncating, splice, and missense variants; WES "broaden[s] the diagnostic spectrum of SOX5-related intellectual disability" and is valuable in genetically heterogeneous ID (PMID: 26111154). WGS/karyotype/FISH are useful when a balanced translocation disrupting SOX5 is suspected (PMID: 29477873). - Targeted SOX5 / NDD gene-panel testing and single-gene testing are options once SOX5 is suspected. - Minigene splicing assays may be used to confirm pathogenicity of splice variants (Lian 2024).

Clinical / supportive tests are for characterization and management, not diagnosis: brain MRI (structural anomalies), ophthalmologic examination (given ~55–57% eye involvement — including OCT/optic-nerve imaging; PMID: 40180173), spine imaging (scoliosis), and EEG if seizures are suspected.

Biomarkers. No specific biochemical biomarker; the diagnostic "biomarker" is the SOX5 genetic lesion itself. No metabolic, proteomic, or metabolomic diagnostic signature is established.

Clinical criteria / differential diagnosis. No formal consensus diagnostic criteria; diagnosis rests on genotype plus compatible phenotype. Differential diagnosis includes other syndromic intellectual-disability/speech-delay disorders with mild dysmorphism (e.g., other transcription-factor haploinsufficiency NDDs), distinguished by molecular testing.

Screening. No population newborn or carrier screening exists (de novo dominant, rare). Cascade testing of parents is warranted after a proband diagnosis to assess inheritance and, importantly, germline-mosaicism-related recurrence risk.

11. Outcome / Prognosis

Survival / mortality. Life expectancy is generally considered not significantly reduced; LAMSHF is not a life-limiting or degenerative disorder, and no disease-specific mortality figures are established. It is compatible with survival to adulthood.

Morbidity / function. Principal long-term morbidity is cognitive and communicative disability (intellectual disability, prominent speech/language impairment) and behavioral challenges (ADHD, ASD traits), plus visual impairment in a majority and orthopedic issues (scoliosis) in a subset. These impose lifelong functional and educational impacts. Formal QoL instruments (EQ-5D, SF-36, PROMIS) have not been applied specifically to this cohort.

Disease course / complications. Static neurodevelopmental course; complications include progressive scoliosis, refractive/optic-nerve visual loss, and seizures in ~22% (Lian 2024). Recovery of core cognitive deficits does not occur, but function can be improved with early intervention.

Prognostic factors. No validated molecular prognostic biomarkers. Zawerton et al. found no clear genotype–phenotype severity correlation, so severity cannot currently be predicted from variant type/location, although HMG-domain missense and truncating/deletion variants are all pathogenic loss-of-function.

12. Treatment

There is no disease-specific or curative therapy. As stated for the closely related presentation, "There is currently no treatment for LSS" [PMID: 40163633]. Management is entirely supportive and multidisciplinary, targeting individual phenotypes:

  • Developmental / rehabilitative (NCIT: Developmental Therapy, Speech Therapy, Occupational Therapy, Physical Therapy): early-intervention programs, speech-language therapy (central given the prominent expressive-language deficit), occupational and physical therapy, and special-education support.
  • Behavioral / pharmacologic: management of ADHD and ASD-associated irritability/aggression. Psychotropic response data are extremely limited. A cautionary case reported risperidone-induced paradoxical agitation in a child with LAMSHF, with subsequent tolerance of aripiprazole — highlighting the need for cautious antipsychotic use and close monitoring (PMID: 41531626). [single case; hypothesis-generating, not generalizable]
  • Ophthalmologic: correction of refractive error (hypermetropia), strabismus management, and monitoring for optic-nerve atrophy/colobomas (PMID: 40180173, 40163633).
  • Orthopedic: surveillance and management of scoliosis and joint hypermobility.
  • Neurological: standard anti-seizure management for the ~22% with epilepsy.

Advanced / experimental therapeutics. No gene, cell, RNA-based, targeted, or immunotherapies exist or are in trials specifically for SOX5 haploinsufficiency. Because the mechanism is haploinsufficiency of a developmental transcription factor acting largely prenatally, therapeutic restoration of dosage postnatally is not currently feasible. No NCT trials targeting the disease mechanism are identified.

Pharmacogenomics / personalized medicine. No established pharmacogenomic guidance; the risperidone/aripiprazole observation (PMID: 41531626) is anecdotal.

13. Prevention

Primary prevention. Not possible for de novo cases (no modifiable risk factors). For families with an affected parent or documented germline mosaicism, options include prenatal diagnosis (CMA/sequencing on chorionic villus or amniotic samples) and preimplantation genetic testing (PGT) for a known familial variant.

Genetic counseling (key preventive/planning intervention). Essential. Counseling should convey (i) predominantly de novo occurrence with typically low but non-negligible recurrence risk, and (ii) the documented possibility of parental gonadal mosaicism, which elevates recurrence risk beyond the general de novo baseline (PMID: 36861937). Cascade testing of parents informs recurrence estimates.

Secondary / tertiary prevention. Early developmental screening and intervention; routine ophthalmologic screening (given majority eye involvement); scoliosis surveillance during growth; and behavioral/educational support to prevent secondary functional decline. No immunization or public-health/environmental interventions are applicable.

14. Other Species / Natural Disease

Taxonomy / orthologs. SOX5 is deeply conserved across vertebrates. Orthologs studied in disease-relevant contexts include mouse Sox5 (NCBI Gene 20678), and sox5 in zebrafish and medaka.

Natural disease. No naturally occurring companion-animal or wildlife disease equivalent to Lamb–Shaffer syndrome is documented (no OMIA entry established for a SOX5 haploinsufficiency phenotype). The value of other species is as experimental models (below), not as natural disease.

Comparative biology / evolutionary conservation. SOX5's developmental functions are evolutionarily conserved: it acts in neural-crest-derived pigment-cell fate in fish (medaka/zebrafish) — "Sox5 functions as a fate switch in medaka pigment cell development" [PMID: 24699463] — and interacts with SoxE factors (Sox8/Sox10) at neural-crest enhancers (PMID: 28012818, 29621239). Its chondrogenic and BMP-cofactor roles are conserved in mouse and Xenopus. This conservation makes cross-species mechanistic findings directly relevant to the human disorder.

Transmission / zoonosis. Not applicable (genetic disorder).

15. Model Organisms

Mouse (Mus musculus; primary mammalian model).* - Sox5 knockout: demonstrates the cortical mechanism — loss causes overlapping corticofugal neuron identities and mistimed subtype generation (PMID: 18215621). Recapitulation: strong for the neurodevelopmental/cortical mechanism; models the cellular basis of the human cognitive phenotype. - Sox5;Sox6* double-null: "Whereas Sox5 and Sox6 single null mice are born with mild skeletal abnormalities, Sox5; Sox6 double null fetuses die with a severe, generalized chondrodysplasia" [PMID: 11702786]. This reveals redundancy and confirms the skeletal role; single-null skeletal phenotype (mild) parallels the mild human musculoskeletal features. Limitation: homozygous double-nulls are embryonic/perinatal-lethal, so they model dosage biology rather than the human heterozygous condition directly. - Cross-network models: Gatad2b-haploinsufficient mice show Sox5 misexpression and abnormal cortical patterning, situating Sox5 in NuRD-regulated corticogenesis (PMID: 38238293).

Fish (zebrafish, medaka). sox5/sox10 mutants dissect neural-crest and pigment-cell fate decisions (PMIDs: 24699463, 29621239, 28012818), and zebrafish cartilage studies place sox5 in the sox9-dependent chondrogenic network (PMID: 26657540). Applications: neural-crest and craniofacial/pigment mechanisms; enhancer-level regulation.

In vitro / amphibian (Xenopus explants). Established SOX5 as a BMP R-Smad cofactor directing ectodermal patterning (PMID: 25453832) and the SOX5/6/9 cooperative activation of cartilage enhancers (PMIDs: 11680692, 11702786) — the biochemical/functional core of the mechanism.

Model limitations overall. No single model reproduces the full human heterozygous multisystem syndrome; models illuminate discrete mechanistic branches (cortical, skeletal, neural-crest). Genotype–phenotype severity determinants remain unmodeled.

Resources: MGI (mouse Sox5), ZFIN (zebrafish sox5), Alliance of Genome Resources.

Mechanistic Model / Synthesis

   Heterozygous SOX5 loss-of-function lesion
   (microdeletion | truncating | splice | HMG-missense | translocation)
         |
         v
~50% functional SOX5  (HAPLOINSUFFICIENCY)
[confirmed: gnomAD pLI=1.00, LOEUF=0.17, LoF Z=7.34]
         |
Reduced SOX5 transcription-factor / cofactor activity
         |
+----------------+------------------------+
v                v                         v
 BRANCH A (CNS)   BRANCH B (skeleton)     BRANCH C (neural crest/BMP)
 Loss of temporal  Weakened SOX5/6/9      Impaired BMP R-Smad cofactor
 brake on cortico- chondrogenic co-       role & NC gene regulation
 fugal neuron      activation (Col2a1,    (Smad1/4 recruitment)
 subtype timing    aggrecan)
|                |                         |
v                v                         v
 Overlapping sub-  Mild cartilage/        Subtle craniofacial /
 plate/CT/SCPN     growth-plate defect    ectodermal / pigment /
 identities                               (ocular?) effects
|                |                         |
v                v                         v
 ID, speech delay, Scoliosis, joint       Facial dysmorphism,
 ASD/ADHD,         hypermobility,         ophthalmic anomalies
 motor delay       short stature          (~55-57%)

Upstream vs downstream: The SOX5 dosage reduction is the single upstream node; the three branches are parallel downstream consequences in different developmental compartments (cortex, cartilage, neural crest). The cortical branch dominates the clinical picture (near-universal cognitive/speech phenotype), consistent with SOX5's non-redundant temporal-identity role in corticogenesis, whereas the skeletal branch is mild because of SOX6 redundancy.

Evidence Base

PMID Study Contribution
22290657 Lamb et al. 2012 — delineation (16 individuals) Defined syndrome; established SOX5 as dosage-sensitive; core phenotype; de novo predominance with rare inheritance
23220431 Schanze et al. 2013 Narrowed critical region to SOX5 alone (120 kb minimal deletion)
31578471 Zawerton et al. 2020 (41 patients) HMG-domain missense variants abolish DNA binding/transactivation; loss-of-function mechanism; no severity genotype–phenotype
37702321 Tenorio-Castaño et al. 2023 (n=111 total) Frequency ranking of features; pain insensitivity & hypermetropia notable
36861937 Edgerley et al. 2023 Gonadal mosaicism; twin pairs; phenotype expansion
40180173 Optic atrophy series 2025 Ophthalmic involvement up to 57%
40163633 Coloboma case 2025 Colobomas as possible ophthalmic feature; "no treatment for LSS"
39075495 Lian et al. 2024 (China) Novel variants incl. splice (minigene-validated); seizures 21/95 (~22%)
18215621 Lai et al. 2008 (mouse) SOX5 controls sequential corticofugal neuron subtype generation
11702786 Smits et al. 2001 (mouse) Sox5;Sox6 essential for cartilage; dosage sensitivity
11680692 Lefebvre et al. 2001 L-Sox5/Sox6/Sox9 cooperatively activate chondrogenic enhancers
25453832 Nordin & LaBonne 2014 (Xenopus) Sox5 is a BMP R-Smad cofactor; recruits Smad1/4 to BMP elements
24699463 Nagao et al. 2014 (medaka) Sox5 neural-crest pigment-cell fate switch (conserved role)
28012818 Murko & Bronner 2017 (chick) Sox5 interacts with Sox8/Sox10 at neural-crest enhancers
29477873 2018 translocation case Balanced translocation disrupting SOX5 recapitulates phenotype
26111154 2015 WES case De novo LoF point mutation; utility of exome sequencing
41531626 2025 case report Risperidone-induced paradoxical agitation; aripiprazole tolerated
38238293 Gatad2b/GAND mouse 2024 Sox5 misexpressed downstream of NuRD in corticogenesis

Evidence-type mix: human clinical genetics (cohorts + case reports), mouse/fish/Xenopus model organisms, in-vitro functional assays, and computational population-constraint (gnomAD). The convergence of all four on a loss-of-function/haploinsufficiency mechanism gives high confidence in the core conclusion.

Limitations and Knowledge Gaps

  1. No genotype–phenotype severity predictor. Zawerton et al. found no clear correlation; clinicians cannot currently prognosticate severity from variant type/location.
  2. Rare-disease ascertainment bias. ~110–130 published cases skew pediatric; true prevalence, incidence, sex ratio, adult outcomes, and life expectancy are unquantified.
  3. Mechanistic gaps in non-cortical branches. The causal links from SOX5 loss to the human ophthalmic and behavioral phenotypes are largely inferred from model organisms; the ophthalmic (neural-crest/optic-nerve) branch in particular is mechanistically speculative.
  4. No episignature / biomarker. No methylation signature or biochemical biomarker exists to aid classification of variants of uncertain significance.
  5. No natural animal disease and no faithful heterozygous model capturing the full multisystem human syndrome.
  6. No QoL data using standardized instruments; therapeutic/psychotropic response evidence is limited to isolated case reports.
  7. No disease-modifying therapy and no realistic route to postnatal dosage correction given the prenatal developmental window.

Proposed Follow-up Experiments / Actions

  1. Establish a prospective natural-history registry (harmonized deep phenotyping + longitudinal outcomes, adult data, standardized QoL/PROMIS) to define prevalence, progression, and prognostic factors.
  2. Systematic variant–function mapping: high-throughput deep-mutational-scanning of SOX5 (DNA-binding + transactivation readouts) to reclassify VUS and test for any residual genotype–phenotype signal beyond the HMG-domain rule.
  3. Search for a DNA-methylation episignature in patient blood (EPIC array) to build a clinical VUS-classification tool, as done for other chromatin/NDD genes.
  4. Patient-derived iPSC → cortical organoids to test whether human SOX5 haploinsufficiency reproduces the mouse corticofugal-identity/timing defect and to enable drug screening.
  5. Ophthalmic mechanism study: conditional/neural-crest Sox5 models plus systematic OCT/optic-nerve phenotyping in patients to determine whether eye findings are neural-crest- or BMP-cofactor-mediated.
  6. Recurrence-risk quantification: systematic parental deep-sequencing across cohorts to estimate the frequency and magnitude of gonadal mosaicism for counseling.
  7. Pharmacovigilance: aggregate psychotropic-response data (registry/FAERS) to test the risperidone-paradoxical-agitation signal and guide behavioral pharmacotherapy.

Report compiled from clinical, model-organism, in-vitro functional, and computational (gnomAD/GTEx) evidence across 34 reviewed papers and 9 confirmed findings. Where a causal step rests on model-organism or in-vitro data rather than direct human demonstration, this is stated explicitly in §6.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 19
Resolved 19
Unresolved (possible confabulation) 0
Unverifiable 0
Quoted claims checked 13
Quoted claims found in source 13
Quoted claims not found in source 0
References weighed for topical relevance 19
On topic 13
Off topic 0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 36
Resolved 35
Unresolved (possible confabulation) 0
Obsolete 0
Unverifiable 1
Terms whose name was checked 17
Terms named correctly 7
Terms named as a different term 7
Terms whose name is worth a second look 3

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

  • MONDO:0017781 (3 mentions) - the report calls it "MONDO"; MONDO calls it 12p12.1 microdeletion syndrome
  • HP:0001270 (1 mention) - the report calls it "Neuromotor"; HP calls it Motor delay
  • HP:0002650 (1 mention) - the report calls it "Skeletal"; HP calls it Scoliosis
  • HP:0001382 (1 mention) - the report calls it "Musculoskeletal"; HP calls it Joint hypermobility
  • HP:0004322 (1 mention) - the report calls it "Growth"; HP calls it Short stature
  • HP:0001250 (1 mention) - the report calls it "Neurological"; HP calls it Seizure
  • HP:0007021 (1 mention) - the report calls it "Sensory"; HP calls it Pain insensitivity

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

  • HP:0001252 (1 mention) - the report calls it "Neuromuscular"; HP calls it Hypotonia, and lists "Muscular hypotonia" among its other names
  • GO:0006357 (1 mention) - the report calls it "regulation of transcription by RNA Pol II"; GO calls it regulation of transcription by RNA polymerase II
  • CL:0000333 (2 mentions) - the report calls it "neural crest cell"; CL calls it migratory neural crest cell